<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
    <front>
        <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id><journal-id journal-id-type="pmc">plosbiol</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Biology</journal-title></journal-title-group><issn pub-type="ppub">1544-9173</issn><issn pub-type="epub">1545-7885</issn><publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, USA</publisher-loc>
            </publisher></journal-meta>
        <article-meta><article-id pub-id-type="publisher-id">10-PLBI-RA-9477R2</article-id><article-id pub-id-type="doi">10.1371/journal.pbio.1000614</article-id><article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline">
                    <subject>Genetics and Genomics/Disease Models</subject>
                    <subject>Neurological Disorders</subject>
                    <subject>Neurological Disorders/Movement Disorders</subject>
                    <subject>Neuroscience/Neurobiology of Disease and Regeneration</subject>
                </subj-group>
            </article-categories><title-group><article-title>Molecular Determinants and Genetic Modifiers of Aggregation and
                    Toxicity for the ALS Disease Protein FUS/TLS</article-title><alt-title alt-title-type="running-head">Mechanisms of FUS Aggregation and
                    Toxicity</alt-title></title-group><contrib-group>
                <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
                    <name name-style="western">
                        <surname>Sun</surname>
                        <given-names>Zhihui</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">
                        <sup>1</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
                    <name name-style="western">
                        <surname>Diaz</surname>
                        <given-names>Zamia</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff2">
                        <sup>2</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Fang</surname>
                        <given-names>Xiaodong</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">
                        <sup>1</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Hart</surname>
                        <given-names>Michael P.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">
                        <sup>1</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Chesi</surname>
                        <given-names>Alessandra</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">
                        <sup>1</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Shorter</surname>
                        <given-names>James</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff2">
                        <sup>2</sup>
                    </xref>
                    <xref ref-type="corresp" rid="cor1">
                        <sup>*</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Gitler</surname>
                        <given-names>Aaron D.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">
                        <sup>1</sup>
                    </xref>
                    <xref ref-type="corresp" rid="cor1">
                        <sup>*</sup>
                    </xref>
                </contrib>
            </contrib-group><aff id="aff1">
                <label>1</label>
                <addr-line>Department of Cell and Developmental Biology, The University of
                    Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of
                    America</addr-line>
            </aff><aff id="aff2">
                <label>2</label>
                <addr-line>Department of Biochemistry and Biophysics, The University of Pennsylvania
                    School of Medicine, Philadelphia, Pennsylvania, United States of
                    America</addr-line>
            </aff><contrib-group>
                <contrib contrib-type="editor" xlink:type="simple">
                    <name name-style="western">
                        <surname>Weissman</surname>
                        <given-names>Jonathan S.</given-names>
                    </name>
                    <role>Academic Editor</role>
                    <xref ref-type="aff" rid="edit1"/>
                </contrib>
            </contrib-group><aff id="edit1">University of California San Francisco/Howard Hughes Medical Institute,
                United States of America</aff><author-notes>
                <corresp id="cor1">* E-mail: <email xlink:type="simple">gitler@mail.med.upenn.edu</email> (ADG); <email xlink:type="simple">jshorter@mail.med.upenn.edu</email> (JS)</corresp>
                <fn fn-type="con">
                    <p>The author(s) have made the following declarations about their contributions:
                        Conceived and designed the experiments: ZS ZD XF MPH JS ADG. Performed the
                        experiments: ZS ZD XF MPH JS ADG. Analyzed the data: ZS ZD XF MPH AC JS ADG.
                        Wrote the paper: JS ADG.</p>
                </fn>
            <fn fn-type="conflict">
                <p>The authors have declared that no competing interests exist.</p>
            </fn></author-notes><pub-date pub-type="collection">
                <month>4</month>
                <year>2011</year>
            </pub-date><pub-date pub-type="epub">
                <day>26</day>
                <month>4</month>
                <year>2011</year>
            </pub-date><volume>9</volume><issue>4</issue><elocation-id>e1000614</elocation-id><history>
                <date date-type="received">
                    <day>16</day>
                    <month>9</month>
                    <year>2010</year>
                </date>
                <date date-type="accepted">
                    <day>17</day>
                    <month>3</month>
                    <year>2011</year>
                </date>
            </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Sun et al</copyright-holder><license><license-p>This is an open-access article distributed under the
                terms of the Creative Commons Attribution License, which permits unrestricted use,
                distribution, and reproduction in any medium, provided the original author and
                source are credited.</license-p></license></permissions><related-article id="RA1" issue="4" page="e1001052" related-article-type="companion" vol="9" xlink:href="info:doi/10.1371/journal.pbio.1001052" xlink:title="Research Article" xlink:type="simple">
                <article-title>A Yeast Model of FUS/TLS-Dependent Cytotoxicity</article-title>
            </related-article><related-article id="RA2" issue="4" page="e1001053" related-article-type="companion" vol="9" xlink:href="info:doi/10.1371/journal.pbio.1001053" xlink:title="Synopsis" xlink:type="simple">
                <article-title>A Yeast Model for Understanding ALS: Fast, Cheap, and Easy to Control</article-title>
            </related-article><abstract abstract-type="toc">
                <p>A combination of yeast genetics and protein biochemistry define how the fused in
                    sarcoma (FUS) protein might contribute to Lou Gehrig's disease.</p>
            </abstract><abstract>
                <p>TDP-43 and FUS are RNA-binding proteins that form cytoplasmic inclusions in some
                    forms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
                    degeneration (FTLD). Moreover, mutations in TDP-43 and FUS are linked to ALS and
                    FTLD. However, it is unknown whether TDP-43 and FUS aggregate and cause toxicity
                    by similar mechanisms. Here, we exploit a yeast model and purified FUS to
                    elucidate mechanisms of FUS aggregation and toxicity. Like TDP-43, FUS must
                    aggregate in the cytoplasm and bind RNA to confer toxicity in yeast. These
                    cytoplasmic FUS aggregates partition to stress granule compartments just as they
                    do in ALS patients. Importantly, in isolation, FUS spontaneously forms pore-like
                    oligomers and filamentous structures reminiscent of FUS inclusions in ALS
                    patients. FUS aggregation and toxicity requires a prion-like domain, but unlike
                    TDP-43, additional determinants within a RGG domain are critical for FUS
                    aggregation and toxicity. In further distinction to TDP-43, ALS-linked FUS
                    mutations do not promote aggregation. Finally, genome-wide screens uncovered
                    stress granule assembly and RNA metabolism genes that modify FUS toxicity but
                    not TDP-43 toxicity. Our findings suggest that TDP-43 and FUS, though similar
                    RNA-binding proteins, aggregate and confer disease phenotypes via distinct
                    mechanisms. These differences will likely have important therapeutic
                    implications.</p>
            </abstract><abstract abstract-type="summary">
                <title>Author Summary</title>
                <p>Many human neurodegenerative diseases are associated with the abnormal
                    accumulation of protein aggregates in the neurons of affected individuals.
                    Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is
                    a fatal human neurodegenerative disease caused primarily by a loss of motor
                    neurons. Recently, mutations in a gene called fused in sarcoma (FUS) were
                    identified in some ALS patients. The basic mechanisms by which FUS contributes
                    to ALS are unknown. We have addressed this question using protein biochemistry
                    and the genetically tractable yeast <italic>Saccharomyces cerevisiae.</italic>
                    We defined the regions of biochemically pure FUS protein that contribute to its
                    aggregation and toxic properties. We then used genome-wide screens in yeast to
                    identify genes and cellular pathways involved in the toxicity of FUS. Many of
                    the FUS toxicity modifier genes that we identified in yeast have clear homologs
                    in humans, suggesting that these might also be relevant for the human disease.
                    Together, our studies provide novel insight into the basic mechanisms associated
                    with FUS aggregation and toxicity. Moreover, our findings open new avenues that
                    could be explored for therapeutic intervention.</p>
            </abstract><funding-group><funding-statement>This work was supported by a grant from the Packard Center for ALS Research at
                    Johns Hopkins (A.D.G. and J.S.), an NIH Director's New Innovator Award
                    1DP2OD004417-01 (A.D.G), NIH R01 NS065317 (A.D.G.), an NIH Director's New
                    Innovator Award 1DP2OD002177-01 (J.S.), NIH R21 NS067354-0110 (J.S.), a
                    University of Pennsylvania Diabetes and Endocrinology Research Center Pilot and
                    Feasibility grant, and an Ellison Medical Foundation New Scholar in Aging Award
                    (J.S.). A.D.G. is a Pew Scholar in the Biomedical Sciences, supported by The Pew
                    Charitable Trusts. The funders had no role in study design, data collection and
                    analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
                <page-count count="25"/>
            </counts></article-meta>
    </front>
    <body>
        <sec id="s1">
            <title>Introduction</title>
            <p>Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is a
                devastating neurodegenerative disease. It is a rapidly progressing motor neuron
                wasting disorder that leads to paralysis and death typically within 2–5 years
                of onset. There are no cures or effective treatments. Given the similarities in
                presentation and pathology of familial and sporadic disease, study of genes mutated
                in familial disease can shed light on mechanisms of both familial ALS and the more
                common sporadic form. The first familial gene associated with ALS was
                    <italic>SOD1</italic>
                <xref ref-type="bibr" rid="pbio.1000614-Rosen1">[1]</xref>, and much
                research over the past 10–15 years has focused on mechanisms by which mutant
                SOD1 may cause motor neuron dysfunction and loss <xref ref-type="bibr" rid="pbio.1000614-Cleveland1">[2]</xref>.</p>
            <p>Insight into ALS changed dramatically in 2006 when the 43 kDa TAR-DNA-binding protein
                (TDP-43) was identified as a protein that accumulates abnormally in the
                ubiquitinated pathological lesions that characterize brain and spinal cord tissue of
                almost every non-<italic>SOD1</italic> ALS patient <xref ref-type="bibr" rid="pbio.1000614-Neumann1">[3]</xref>–<xref ref-type="bibr" rid="pbio.1000614-ChenPlotkin1">[5]</xref>. Similar TDP-43 inclusions
                were also identified in degenerating neurons in a subset of frontotemporal lobar
                degeneration (FTLD-TDP) cases <xref ref-type="bibr" rid="pbio.1000614-Neumann1">[3]</xref>–<xref ref-type="bibr" rid="pbio.1000614-ChenPlotkin1">[5]</xref>. TDP-43 is an RNA-binding
                protein with two RNA recognition motifs (RRMs) and a glycine rich domain <xref ref-type="bibr" rid="pbio.1000614-Pesiridis1">[6]</xref>. In 2008,
                several groups independently reported the identification of over 30 different
                mutations in the TDP-43 gene (<italic>TARDBP</italic>) in various sporadic and
                familial ALS patients <xref ref-type="bibr" rid="pbio.1000614-Pesiridis1">[6]</xref>–<xref ref-type="bibr" rid="pbio.1000614-VanDeerlin1">[10]</xref>. TDP-43 mutations were subsequently identified in various
                FTLD-TDP cases <xref ref-type="bibr" rid="pbio.1000614-Benajiba1">[11]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Kovacs1">[12]</xref>. Taken together, these studies strongly suggest that
                TDP-43 is a new human neurodegenerative disease protein. Wild-type (WT) TDP-43
                accumulates abnormally in cytoplasmic, ubiquitinated inclusions in degenerating
                neurons of ALS and FTLD-TDP patients, and mutations in the TDP-43 gene are linked
                with disease in rare familial and sporadic cases. Despite these advances, how TDP-43
                contributes to disease, which domain of TDP-43 drives aggregation, and how
                ALS-linked mutations affect TDP-43 function and aggregation remained unclear.</p>
            <p>To address these deficits, we investigated the pathogenic properties of TDP-43 in
                yeast. The yeast system is simple and fast and has highly conserved fundamental
                pathways that allow powerful insights into complex human neurodegenerative diseases
                such as Parkinson's disease, Alzheimer's disease, and ALS <xref ref-type="bibr" rid="pbio.1000614-Gitler1">[13]</xref>. Therefore, we
                developed a yeast model of TDP-43 to study TDP-43 biology as well as the mechanisms
                of TDP-43 aggregation and toxicity. Expression of human TDP-43 in yeast resulted in
                cytoplasmic aggregation and toxicity, thus modeling key aspects of human TDP-43
                proteinopathies. These studies revealed that RRM2 and the C-terminal domain of
                TDP-43 (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>) are required
                for aggregation and toxicity <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>. Notably, all but one of over 30 ALS-linked mutations
                reside in the C-terminal domain, which the yeast system defined as critical for
                toxicity. Moreover, a combination of pure protein studies and in vivo analyses in
                yeast demonstrated that ALS-linked TDP-43 mutations render TDP-43 more
                aggregation-prone and enhance toxicity <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>. These studies demonstrated
                that the aggregation propensity and severity of toxicity of TDP-43 variants observed
                in ALS could be recapitulated in yeast. Moreover, we have discovered a potent
                genetic modifier of TDP-43 toxicity in yeast, Pbp1, which is connected with ALS in
                humans <xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>. The
                human homolog of Pbp1, ataxin 2, harbors a polyglutamine tract that is greatly
                expanded (&gt;34 glutamines) in spinocerebellar ataxia type 2 <xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>. Importantly,
                intermediate-length polyQ expansions (∼27–33 glutamines) in ataxin 2 are a
                significant genetic risk factor for ALS in humans <xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>. Clearly, the power of yeast
                genetics can be exploited to define basic disease mechanisms of fundamental
                importance to human neurodegenerative disease.</p>
            <fig id="pbio-1000614-g001" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g001</object-id>
                <label>Figure 1</label>
                <caption>
                    <title>Yeast FUS model.</title>
                    <p>(A) Schematic of domain architecture of FUS and TDP-43. Note that both
                        contain glycine-rich regions, RRM, and prion-like domains. In addition, FUS
                        has two RGG domains. (B) Schematic of galactose-inducible construct to
                        express human FUS fused to YFP. (C) Yeast cells expressing YFP alone or
                        YFP-tagged human RNA-binding proteins. Not all RNA-binding proteins
                        aggregate when expressed in yeast. For example, three related human
                        RRM-containing proteins did not form inclusions when expressed in yeast.
                        Instead they were diffusely localized: PPIE localized to the nucleus and
                        cytoplasm; DND1 localized to the cytoplasm; and DNAJC17 was restricted to
                        the nucleus. The ALS disease proteins, TDP-43 and FUS, formed multiple
                        cytoplasmic foci when expressed in yeast. (D) Immunoblot showing untagged
                        and YFP-tagged FUS expression. (E) FUS is toxic when expressed in yeast
                        cells compared to YFP alone control. 5-fold serial dilutions of yeast cells
                        expressing YFP alone, untagged FUS, or YFP-tagged FUS. Because of the
                        galactose-inducible promoter, FUS expression is repressed when cells are
                        grown in the presence of glucose (left panel, FUS expression
                        “off”) and induced when grown in the presence of galactose
                        (right panel, FUS expression “on”). (F) Fusing the strong
                        heterologous SV40 NLS to the N-terminus of FUS restricts it mostly to the
                        nucleus. (G) Spotting assay shows that nuclear-localized SV40 FUS-YFP is
                        less toxic than WT FUS.</p>
                </caption>
                <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g001" xlink:type="simple"/>
            </fig>
            <p>Shortly following the identification of mutations in TDP-43 in ALS, mutations in
                another gene encoding an RNA-binding protein, FUS (fused in sarcoma; also known as
                TLS, translocated in liposarcoma), were connected to familial ALS <xref ref-type="bibr" rid="pbio.1000614-Kwiatkowski1">[17]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Vance1">[18]</xref>. Additional
                mutations in FUS have recently been identified in sporadic ALS cases and in a subset
                of frontotemporal lobar degeneration (FTLD-FUS) cases <xref ref-type="bibr" rid="pbio.1000614-Broustal1">[19]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Mackenzie1">[20]</xref>. FUS is normally a nuclear
                protein, but ALS patients harboring FUS mutations exhibit prominent neuronal
                cytoplasmic FUS accumulations that appear devoid of TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Vance1">[18]</xref>. Several other examples of
                neurodegenerative disease are beginning to emerge where the predominant disease
                phenotype is the cytoplasmic aggregation of wild-type FUS. These include some cases
                of juvenile ALS <xref ref-type="bibr" rid="pbio.1000614-Huang1">[21]</xref>, basophilic inclusion body disease <xref ref-type="bibr" rid="pbio.1000614-Munoz1">[22]</xref>, as well as the majority of tau-
                and TDP-43-negative frontotemporal lobar degeneration cases <xref ref-type="bibr" rid="pbio.1000614-Urwin1">[23]</xref>. Moreover, FUS is also
                aggregated in Huntington's disease; spinocerebellar ataxia (SCA) type 1, 2, and
                3; and dentatorubropallidoluysian atrophy <xref ref-type="bibr" rid="pbio.1000614-Doi1">[24]</xref>,. These findings extend the
                spectrum of disorders associated with FUS aggregation beyond ALS and FTLD-FUS and
                suggest the importance of understanding mechanisms of aggregation of WT as well as
                mutant FUS.</p>
            <p>FUS was initially discovered as part of a chromosomal translocation associated with
                human myxoid liposarcomas <xref ref-type="bibr" rid="pbio.1000614-Crozat1">[26]</xref>. Subsequent studies have revealed roles for FUS in
                transcription, RNA processing, and RNA transport <xref ref-type="bibr" rid="pbio.1000614-Zinszner1">[27]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Bertolotti1">[29]</xref>. In neurons, FUS is
                localized to the nucleus but is transported to dendritic spines at excitatory
                post-synapses in a complex with RNA and other RNA-binding proteins <xref ref-type="bibr" rid="pbio.1000614-Fujii1">[30]</xref>. In further
                support of a role of FUS in maintaining neuronal architecture, primary hippocampal
                neurons cultured from FUS knockout mouse embryos display defects in spine morphology
                and decreased spine density <xref ref-type="bibr" rid="pbio.1000614-Fujii2">[31]</xref>. It remains unclear, however, how loss of this function
                of FUS or perhaps a novel toxic gain-of-function associated with FUS mutations
                contribute to ALS. Importantly, it is also uncertain whether FUS is intrinsically
                aggregation-prone. Indeed, FUS might simply be a marker of disease that is
                sequestered by other aggregated components.</p>
            <p>FUS and TDP-43 possess a similar domain structure. Like TDP-43, FUS has an RRM and a
                glycine-rich domain (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>).
                Moreover, using a bioinformatic algorithm designed to identify yeast prion domains
                    <xref ref-type="bibr" rid="pbio.1000614-Alberti1">[32]</xref>, we
                recently identified novel “prion-like” domains in the N-terminal domain
                of FUS (amino acids 1–239) and in the C-terminal domain of TDP-43 (amino acids
                277–414) (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>, <xref ref-type="supplementary-material" rid="pbio.1000614.s001">Figure S1</xref>)
                    <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>. Similar
                to prion domains found in yeast prion proteins such as Sup35, Ure2, and Rnq1, this
                domain is enriched in uncharged polar amino acids (especially asparagine, glutamine,
                and tyrosine) and glycine <xref ref-type="bibr" rid="pbio.1000614-Alberti1">[32]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Shorter1">[34]</xref>. This type of domain encodes all the information
                necessary to form a prion in yeast <xref ref-type="bibr" rid="pbio.1000614-Zinszner1">[27]</xref>–. It should be noted,
                however, that this type of domain is not found in all prion proteins, including
                HET-s from <italic>Podospora anserina</italic> and mammalian prion protein (PrP)
                    <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Shorter1">[34]</xref>. Remarkably,
                by using this bioinformatic algorithm <xref ref-type="bibr" rid="pbio.1000614-Alberti1">[32]</xref> to score and rank the human
                proteome (27,879 human proteins) for prion-like properties, FUS and TDP-43 ranked
                    15<sup>th</sup> and 69<sup>th</sup>, respectively <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>. Our findings raise the
                intriguing possibility that RRM proteins with predicted prion-like domains may be
                particularly relevant to ALS <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Fuentealba1">[35]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Udan1">[36]</xref>. Virtually all the ALS-linked mutations in TDP-43 lie in
                its prion-like domain <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>. By contrast, only a few of the ALS-linked mutations in
                FUS lie in its prion-like domain <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>. Indeed, the majority of ALS-linked FUS mutations reside
                at the extreme C-terminal region <xref ref-type="bibr" rid="pbio.1000614-LagierTourenne1">[37]</xref>. The identification of
                two RNA-binding proteins with a similar domain architecture that aggregate and are
                sometimes mutated in ALS and FTLD gives rise to the emerging concept that RNA
                metabolic pathways may play a major role in ALS and FTLD pathogenesis <xref ref-type="bibr" rid="pbio.1000614-LagierTourenne2">[38]</xref>.</p>
            <p>Despite these similarities between TDP-43 and FUS, it is unknown whether TDP-43 and
                FUS aggregate and cause toxicity by similar mechanisms. Here, we address this issue
                and establish, for the first time, two vital weapons in the fight against FUS
                proteinopathies, which have been critical in advancing our basic understanding of
                various other protein misfolding disorders, including Parkinson's disease,
                Huntington's disease, and TDP-43 proteinopathies <xref ref-type="bibr" rid="pbio.1000614-Gitler1">[13]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Cooper1">[39]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Willingham1">[45]</xref>. First, we establish a
                simple yeast model of FUS aggregation and toxicity. Second, we reconstitute FUS
                misfolding and aggregation using pure protein. These two approaches have served as
                important foundations for understanding mechanistic aspects of numerous
                neurodegenerative disorders and have empowered countless advances. We establish
                that, as for TDP-43, the RRM and the prion-like domain of FUS are required for
                aggregation and toxicity in yeast. However, in contrast to TDP-43, we find that
                additional determinants within the first RGG domain (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>) are also critical for FUS aggregation
                and toxicity. Importantly, we demonstrate that pure FUS is inherently
                aggregation-prone in the absence of other components and this behavior requires
                determinants in the prion-like domain and first RGG domain of FUS (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>). Aggregates formed by
                pure FUS are filamentous and resemble those formed by FUS in degenerating motor
                neurons of ALS patients. ALS-linked TDP-43 mutations can promote aggregation in
                vitro with pure proteins and in yeast <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>. By contrast, we find that
                ALS-linked FUS mutations do not promote aggregation per se. Finally, using two
                genome-wide screens in yeast, we identified several genes and pathways as potent
                modifiers of FUS toxicity. Many of the genes that we discovered in the yeast screens
                have human homologs. Thus, they are likely to provide insight into the specific
                cellular pathways perturbed by FUS accumulation and may ultimately suggest novel
                avenues for therapeutic investigation. Surprisingly, almost all of the genetic
                modifiers had no effect on TDP-43 toxicity in yeast. These key differences between
                FUS and TDP-43 will help guide the design of therapeutic interventions aimed at
                mitigating FUS aggregation in disease.</p>
        </sec>
        <sec id="s2">
            <title>Results</title>
            <sec id="s2a">
                <title>FUS Forms Inclusions in the Yeast Cytoplasm and Is Toxic</title>
                <p>To model aspects of FUS pathology in yeast, we first transformed yeast cells with
                    a high-copy 2 micron (2 µ) plasmid containing human FUS fused to the
                    yellow fluorescent protein (YFP; <xref ref-type="fig" rid="pbio-1000614-g001">Figure 1B</xref>). Because TDP-43 was toxic to yeast <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>, we placed FUS-YFP
                    expression under the control of a tightly regulated galactose-inducible promoter
                        (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1B</xref>) to prevent
                    deleterious effects during routine passage. After growing transformants in
                    non-inducing conditions (raffinose media), we induced expression of FUS-YFP in
                    galactose-containing media. Overexpression is a common tool to study the
                    aggregation and toxicity of numerous proteins ranging from alpha-synuclein to
                    TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Cooper1">[39]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Willingham1">[45]</xref>. It provides a method to elicit protein misfolding by
                    increasing protein concentration and exceeding proteostatic buffers <xref ref-type="bibr" rid="pbio.1000614-Powers1">[46]</xref>. Moreover,
                    overexpression is likely to yield key information because an established cause
                    of several human neurodegenerative diseases is increased expression of
                    aggregation-prone proteins, such as alpha-synuclein, amyloid precursor protein,
                    and TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Gitcho2">[47]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Cabrejo1">[49]</xref>. Following 4–6 h of
                    induction, we visualized FUS-YFP localization by fluorescence microscopy (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1C</xref>). Whereas the
                    control, YFP alone, was localized diffusely throughout the cytoplasm and
                    nucleus, FUS-YFP localized to the cytoplasm where it formed numerous foci (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1C</xref>). FUS-YFP showed a
                    similar cytoplasmic localization pattern when expressed from a low-copy
                    galactose-inducible CEN plasmid (unpublished data). The FUS localization pattern
                    was strikingly similar to that of TDP-43 in yeast (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1C</xref> and <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>), in terms of size, shape,
                    and quantity of foci in the cytoplasm (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1C</xref>). Indeed when co-expressed in the
                    same cell, FUS-YFP and TDP-43-CFP co-localized to the same cytoplasmic foci
                        (<xref ref-type="supplementary-material" rid="pbio.1000614.s002">Figure
                        S2</xref>). Thus, TDP-43 and FUS inclusions partition to a similar
                    compartment in yeast.</p>
                <p>Next, we employed a weaker promoter (glyceraldehyde-3-phosphate dehydrogenase
                    (GPD) promoter) to express FUS at lower levels. Here, FUS-YFP localized to both
                    the nucleus and cytoplasm, where it was diffusely distributed (<xref ref-type="supplementary-material" rid="pbio.1000614.s003">Figure S3</xref>).
                    Similar results were seen with even weaker yeast promoters (CYC1 and NOP1;
                    unpublished data). Thus, the FUS expression level plays a key role in FUS
                    localization and aggregation in yeast. These data predict that sequence variants
                    or copy number variants in the FUS gene that increase FUS expression might also
                    contribute to ALS, FTLD-FUS, and other FUS proteinopathies. Indeed, a variant in
                    the 3′UTR of the TDP-43 gene increases TDP-43 expression and contributes
                    to FTLD-TDP <xref ref-type="bibr" rid="pbio.1000614-Gitcho2">[47]</xref>. Moreover, motor neurons express higher levels of FUS
                    than other tissues, which might render them more vulnerable to FUS misfolding
                    events <xref ref-type="bibr" rid="pbio.1000614-Huang2">[50]</xref>.</p>
                <p>In mammalian cells, FUS is normally restricted to the nucleus <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Ito1">[55]</xref>. By contrast,
                    in yeast, FUS is mostly localized to the cytoplasm. This difference suggests
                    that the non-canonical FUS nuclear localization signal (NLS; amino acids
                    500–526) might not be very efficient in yeast. Indeed, in an accompanying
                    manuscript, Ju et al. present data that directly support this hypothesis <xref ref-type="bibr" rid="pbio.1000614-Ju1">[56]</xref>. Alternatively,
                    FUS might require post-translational modifications to localize to the nucleus,
                    which do not occur in yeast. In an effort to restrict FUS to the nucleus, we
                    fused a strong heterologous NLS (the SV40 NLS <xref ref-type="bibr" rid="pbio.1000614-Goldfarb1">[57]</xref>) to the N-terminus of
                    FUS. The SV40 NLS was sufficient to largely restrict FUS to the nucleus, but
                    some cytoplasmic localization was also observed (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1F</xref>). Importantly, restricting FUS to
                    the nucleus eliminated aggregation (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1F</xref>). Thus, FUS accumulation in the cytoplasm contributes to
                    its aggregation. Despite the differences between FUS localization in yeast and
                    mammalian cells, we can clearly use the genetically tractable yeast system to
                    model FUS cytoplasmic aggregation, a critical pathological event in ALS and FTLD
                        <xref ref-type="bibr" rid="pbio.1000614-Kwiatkowski1">[17]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Vance1">[18]</xref>. Furthermore, defective nuclear import of FUS might
                    be a key upstream event in ALS <xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>.</p>
                <p>Having established that FUS, like TDP-43, forms cytoplasmic inclusions when
                    expressed in yeast, we next asked if cytoplasmic aggregation of FUS was toxic.
                    To assess FUS toxicity, we performed spotting assays on galactose media.
                    Expressing FUS-YFP or untagged FUS inhibited growth, whereas YFP had no effect
                        (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1E</xref>). Thus, as
                    for TDP-43, FUS expression in yeast was cytotoxic. Cytotoxicity correlated
                    positively with cytoplasmic aggregation. First, expressing FUS at lower levels
                    from the GPD promoter did not induce cytoplasmic FUS inclusions (<xref ref-type="supplementary-material" rid="pbio.1000614.s003">Figure S3</xref>)
                    and did not confer toxicity (unpublished data). Second, restricting FUS to the
                    nucleus with the SV40 NLS (<xref ref-type="fig" rid="pbio-1000614-g001">Figure
                        1F</xref>) greatly reduced toxicity (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1G</xref>). These data suggest that
                    cytoplasmic FUS aggregation is a critical pathological event in ALS and that
                    neurodegeneration might be caused by a toxic gain of function in the
                    cytoplasm.</p>
                <p>Importantly, not every human RNA-binding protein aggregates and is toxic when
                    expressed at high levels in yeast. Indeed, we expressed 132 human proteins
                    containing RRMs in yeast. Of these, 35 (including TDP-43 and FUS) aggregated and
                    were toxic (A.D.G. unpublished observations; <xref ref-type="fig" rid="pbio-1000614-g001">Figure 1C</xref>). It will be important to determine
                    whether any of these RRM-bearing proteins, aside from FUS and TDP-43, are
                    connected to neurodegenerative disease. Moreover, it will be important to define
                    whether common sequence determinants among these 35 RRM-bearing proteins promote
                    aggregation and toxicity. One striking feature of FUS and TDP-43, as well as at
                    least seven other human RNA-binding proteins that are toxic and aggregate in
                    yeast, is the presence of a prion-like domain (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>; A.D.G. unpublished observations)
                        <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>.</p>
            </sec>
            <sec id="s2b">
                <title>FUS Associates with Stress Granules and P-Bodies in Yeast</title>
                <p>We noticed that FUS-YFP cytoplasmic accumulations in yeast are highly dynamic
                    under various growth conditions (Z.S., X.D.F., and A.D.G., unpublished
                    observations). This dynamic behavior was reminiscent of RNA processing bodies
                    (P-bodies) and stress granules. P-bodies and stress granules play important
                    roles in regulating the translation, degradation, and localization of mRNAs. The
                    pathways regulating the incorporation of RNAs and RNA-binding proteins into
                    these structures are highly conserved from yeast to human <xref ref-type="bibr" rid="pbio.1000614-Buchan1">[58]</xref>. Under various stress
                    situations, including heat shock and oxidative stress, TDP-43 and FUS localize
                    to these transient subcellular compartments and sites of RNA processing <xref ref-type="bibr" rid="pbio.1000614-Colombrita1">[59]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Freibaum1">[62]</xref>. Moreover, even under
                    normal conditions some ALS-linked FUS mutants localize to stress granules <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Ito1">[55]</xref>. Thus, we
                    tested whether FUS could induce stress granule or P-body formation in yeast and
                    whether FUS localized to these structures. We expressed FUS-YFP or YFP alone in
                    yeast cells harboring RFP- or CFP-tagged stress granule or P-body markers (<xref ref-type="fig" rid="pbio-1000614-g002">Figure 2</xref>). To detect stress
                    granules we used Pbp1-CFP and to detect P-bodies we used Dcp2-RFP <xref ref-type="bibr" rid="pbio.1000614-Buchan2">[63]</xref>. Expressing
                    YFP alone did not affect the localization of the P-body or stress granule
                    components, which were diffuse under normal conditions (<xref ref-type="fig" rid="pbio-1000614-g002">Figure 2A,B</xref>; unpublished data). However, FUS
                    expression induced the formation of P-bodies and stress granules and FUS-YFP
                    colocalized with both of these structures (<xref ref-type="fig" rid="pbio-1000614-g002">Figure 2A,B</xref>). Thus, FUS localizes to and
                    induces the formation of RNA granules in yeast as it does in human cells <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Gal1">[53]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Ito1">[55]</xref>. These RNA
                    granule assembly pathways are highly conserved from human to yeast. Thus, yeast
                    provides a powerful system to dissect how FUS associates with these structures
                    and to identify genetic and chemical modifiers of this process.</p>
                <fig id="pbio-1000614-g002" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g002</object-id>
                    <label>Figure 2</label>
                    <caption>
                        <title>FUS associates with stress granules and P-bodies in yeast.</title>
                        <p>(A) Yeast cells expressing YFP alone (top row) or FUS-YFP (bottom row).
                            Dcp2-RFP was used to monitor P-body formation and localization. FUS-YFP
                            expression induced the formation of P-bodies and FUS-YFP cytoplasmic
                            localized to these structures. (B) FUS also induced the formation of and
                            localized to stress granules, as monitored by a CFP-fusion to the stress
                            granule protein Pbp1. Similar results were observed with independent
                            P-body and stress granule markers, Lsm1 and Pub1, respectively
                            (unpublished data).</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g002" xlink:type="simple"/>
                </fig>
            </sec>
            <sec id="s2c">
                <title>Defining the Regions of FUS That Contribute to Aggregation and Toxicity in
                    Yeast</title>
                <p>To determine sequence features of FUS that were sufficient and necessary for
                    aggregation and toxicity in yeast, we next performed a structure-function
                    analysis. We recently used a similar approach for TDP-43 and determined that the
                    C-terminal prion-like domain was required for aggregation and toxicity <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>.
                    Underscoring the power of this approach, similar results have been reported for
                    the C-terminal domain of TDP-43 in mammalian cells and in animal models <xref ref-type="bibr" rid="pbio.1000614-Zhang1">[64]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Igaz1">[65]</xref>. Moreover,
                    all but one of the recently identified human ALS-linked TDP-43 mutations are
                    located in this same C-terminal region <xref ref-type="bibr" rid="pbio.1000614-Pesiridis1">[6]</xref>. We generated a series of
                    FUS truncations (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3A</xref>).
                    We expressed each of the truncated FUS constructs as YFP-fusions and determined
                    their subcellular localization (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>) and toxicity (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>). Immunoblotting confirmed that all
                    of the fusion proteins were expressed at comparable levels (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3C</xref>; unpublished data).</p>
                <fig id="pbio-1000614-g003" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g003</object-id>
                    <label>Figure 3</label>
                    <caption>
                        <title>Defining the sequence features contributing to FUS aggregation and
                            toxicity in yeast.</title>
                        <p>(A) A diagram illustrating the domain structure of FUS along with
                            truncation constructs used in this study. (B) Testing the effects of
                            truncations on FUS localization by fluorescence microscopy. The
                            C-terminal domain is required for cytoplasmic localization and
                            aggregation (compare constructs 1–373 and 1–526). Arrows
                            point to larger cytoplasmic FUS inclusions and arrowheads point to cells
                            with more diffuse cytoplasmic FUS with small foci (see table in panel
                            A). (C) Immunoblot showing expression levels of full-length FUS and each
                            truncation. (D) The effects of truncations on toxicity were assessed by
                            spotting assays. As for aggregation, the C-terminal region is required
                            for toxicity but by itself is not sufficient (construct 368–526).
                            The RRM, glycine-rich region and most of the prion-like domain (see
                                <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>) are also required for FUS toxicity (compare
                            constructs 1–501, 50–526, and 100–526). RRM, RNA
                            recognition motif. (E) Mutating conserved phenylalanine residues in the
                            FUS RRM to leucine to abolish RNA binding (FUS<sub>RRM mutant</sub>)
                            does not affect FUS aggregation in yeast, however RNA binding is
                            important for FUS toxicity because the FUS<sub>RRM mutant</sub>
                            eliminates toxicity in yeast (F).</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g003" xlink:type="simple"/>
                </fig>
                <p>Full-length FUS formed multiple cytoplasmic inclusions in yeast (<xref ref-type="fig" rid="pbio-1000614-g001">Figures 1C</xref>, <xref ref-type="fig" rid="pbio-1000614-g003">3B</xref>). Interestingly, removing
                    the last 25 residues of FUS, which harbor most of the ALS-linked mutations <xref ref-type="bibr" rid="pbio.1000614-LagierTourenne1">[37]</xref>,
                    did not affect aggregation (<xref ref-type="fig" rid="pbio-1000614-g003">Figure
                        3B</xref>, construct 1–501). This result is consistent with a recent
                    report that a similar FUS truncation mutant (R495X) is connected with a severe
                    ALS phenotype <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>. A larger C-terminal deletion also had little effect
                    on cytoplasmic aggregation (<xref ref-type="fig" rid="pbio-1000614-g003">Figure
                        3B</xref>, construct 1–453). Thus, C-terminal portions of FUS are not
                    essential for cytoplasmic aggregation.</p>
                <p>For TDP-43, the C-terminal prion-like domain is necessary but not sufficient for
                    cytoplasmic aggregation <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>. TDP-43 also requires a portion of RRM2 (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>) <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>. However,
                    for FUS, the N-terminal prion-like domain and the RRM resulted in an entirely
                    nuclear localized protein (<xref ref-type="fig" rid="pbio-1000614-g003">Figure
                        3B</xref>, construct 1–373; <xref ref-type="supplementary-material" rid="pbio.1000614.s004">Figure S4</xref>). Adding back the first RGG domain
                    (amino acids 371–422) was sufficient to restore cytoplasmic aggregation
                        (<xref ref-type="fig" rid="pbio-1000614-g002">Figure 3B</xref>, construct
                    1–422). Thus, in contrast to our findings with TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>, the
                    prion-like domain and the RRM of FUS (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>, construct 1–373) were
                    insufficient to confer cytoplasmic aggregation. Additional C-terminal
                    determinants within the first RGG domain are required to confer cytoplasmic
                    aggregation (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>,
                    construct 1–422).</p>
                <p>Next, we asked if deletion of portions of the N-terminal prion-like domain of
                    FUS, which spans the QGSY-rich domain and a portion of the Gly-rich domain
                    (amino acids 1–239) (<xref ref-type="fig" rid="pbio-1000614-g001">Figure
                        1A</xref>), prevented aggregation. Indeed, the generation of large
                    cytoplasmic inclusions required most of the N-terminal QGSY-rich domain (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>, compare constructs
                    1–501, 50–526, 100–526, and 165–526) (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3A,B</xref>). Deletion of the
                    entire N-terminal QGSY-rich domain (construct 165–526) yielded mostly
                    diffuse cytoplasmic staining with occasional small foci (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3A,B</xref>). However, shorter N-terminal
                    constructs comprising just the N-terminal QGSY-rich domain or this domain plus
                    the Gly-rich domain did not aggregate and were localized in the nucleus (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>, constructs
                    1–168 and 1–269; <xref ref-type="supplementary-material" rid="pbio.1000614.s004">Figure S4</xref>). Thus, the N-terminal prion-like
                    domain of FUS is necessary but not sufficient for aggregation. Rather, FUS
                    requires sequences in both the N-terminal region and the C-terminal region for
                    robust formation of large cytoplasmic inclusions. Accordingly, large N-terminal
                    deletions were diffusely localized within the cytoplasm, with only occasional
                    small cytoplasmic puncta (<xref ref-type="fig" rid="pbio-1000614-g003">Figure
                        3B</xref>, constructs 165–526, 267–526, 285–526, and
                    368–526). Thus, in distinction to TDP-43, which requires its C-terminal
                    prion-like domain and a portion of RRM2 (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>) to aggregate in yeast <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>, FUS
                    requires its N-terminal prion-like domain, RRM, and first RGG domain to
                    aggregate in yeast (<xref ref-type="fig" rid="pbio-1000614-g001">Figures
                        1A</xref>, <xref ref-type="fig" rid="pbio-1000614-g003">3A</xref>). This key
                    difference will have important implications for the design of therapeutic
                    strategies aimed at preventing or reversing aggregation.</p>
            </sec>
            <sec id="s2d">
                <title>The Domains of FUS Required for Aggregation in Yeast Contribute to
                    Aggregation in Mammalian Cells</title>
                <p>Our domain mapping experiments in yeast indicate that the first RGG domain of FUS
                    (amino acids 371–422) is important for driving aggregation (e.g., <xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>, compare constructs
                    1–373 and 1–422) and that sequences in the N-terminal prion-like
                    domain (amino acids 1–239) are also important (e.g., <xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>, compare constructs 50–526
                    and 165–526). To test these predictions in mammalian cells, we transfected
                    several of these deletion constructs (as C-terminal V5 epitope tag fusions) in
                    COS-7 cells. In contrast to yeast cells, where full-length FUS (construct
                    1–526) forms cytoplasmic inclusions, and consistent with previous reports
                    in mammalian cells <xref ref-type="bibr" rid="pbio.1000614-Kwiatkowski1">[17]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Vance1">[18]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>, full-length FUS localized almost exclusively to the
                    nucleus, forming occasional cytoplasmic foci (<xref ref-type="fig" rid="pbio-1000614-g004">Figure 4</xref>). This difference between the
                    localization of full-length FUS in yeast (almost entirely cytoplasmic and forms
                    inclusions) versus mammalian cells (almost entirely nuclear and diffuse) is also
                    seen with TDP-43 (e.g., compare <xref ref-type="bibr" rid="pbio.1000614-Ayala1">[66]</xref> and <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>) and might reflect differences in the efficacy of the
                    FUS and TDP-43 nuclear localization signals in yeast and mammals. Indeed, Ju et
                    al. demonstrate that the FUS NLS (amino acids 500–526) is ineffective in
                    yeast <xref ref-type="bibr" rid="pbio.1000614-Ju1">[56]</xref>.</p>
                <fig id="pbio-1000614-g004" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g004</object-id>
                    <label>Figure 4</label>
                    <caption>
                        <title>FUS domains that contribute to aggregation in mammalian
                            cells.</title>
                        <p>V5-tagged FUS expression constructs were transfected into COS-7 cells and
                            their localization determined by fluorescence microscopy. Full-length
                            FUS (1–526) localized to the nucleus, consistent with previous
                            reports <xref ref-type="bibr" rid="pbio.1000614-Kwiatkowski1">[17]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Vance1">[18]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. Deletion
                            constructs 1–269 and 1–373 also localized to the nucleus,
                            consistent with our results in yeast (see <xref ref-type="fig" rid="pbio-1000614-g002">Figure 2</xref>). Also as in yeast, the
                            addition of sequences in the first FUS RGG domain resulted in FUS
                            aggregation in the cytoplasm (construct 1–422, arrows). Construct
                            50–526 also aggregated in the cytoplasm, however the morphology of
                            the inclusions (arrowheads) was distinct from that of 1–422.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g004" xlink:type="simple"/>
                </fig>
                <p>Consistent with our yeast data, FUS constructs 1–269 and 1–373
                    localized almost exclusively to the nucleus in a diffuse pattern, although there
                    was more cytoplasmic staining with 1–373 (<xref ref-type="fig" rid="pbio-1000614-g004">Figure 4</xref>). These results were surprising
                    since these constructs lack the C-terminal NLS defined in other studies <xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Kino1">[54]</xref>. However,
                    these results are consistent with those of Kino et al., who find that FUS
                    1–278 is localized to the nucleus and FUS 1–360 is localized to the
                    nucleus as well as the cytoplasm <xref ref-type="bibr" rid="pbio.1000614-Kino1">[54]</xref>. These data suggest that additional determinants of
                    nuclear localization exist in the FUS primary sequence. Indeed, scanning the FUS
                    primary sequence using NLStradumus <xref ref-type="bibr" rid="pbio.1000614-NguyenBa1">[67]</xref> revealed three NLS
                    sequences in FUS comprising residues 241–251, 381–395, and
                    480–521. These two additional NLS sequences (241–251 and
                    381–395) might help explain why all of the FUS constructs in <xref ref-type="fig" rid="pbio-1000614-g004">Figure 4</xref> have some ability to
                    localize to the nucleus.</p>
                <p>Strikingly, as we observed in yeast, addition of the first RGG domain (construct
                    1–422) resulted in prominent cytoplasmic FUS aggregation in COS-7 cells
                        (<xref ref-type="fig" rid="pbio-1000614-g004">Figure 4</xref>). FUS
                    construct 50–526 aggregated in yeast (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>) and mammalian cells (<xref ref-type="fig" rid="pbio-1000614-g004">Figure 4</xref>). However, the
                    morphology of the 50–526 inclusions was distinct from those formed by
                    1–422 (one or two large tight inclusions per cell with 1–422 versus
                    numerous amorphous inclusions with 50–526). These data indicate that the
                    domains of FUS required for aggregation in yeast (especially the first RGG
                    domain) are also critical for FUS aggregation in mammalian cells. Moreover,
                    these data validate the yeast system as a useful platform for interrogating
                    mechanisms and genetic modifiers (see below) of FUS aggregation and
                    toxicity.</p>
            </sec>
            <sec id="s2e">
                <title>Defining the Domains of FUS Required for Toxicity in Yeast</title>
                <p>Having determined the regions of FUS required for aggregation in yeast, we next
                    determined which regions of FUS contributed to toxicity (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>). As with FUS aggregation, the last
                    25 amino acids of FUS, where many of the ALS-linked mutations occur <xref ref-type="bibr" rid="pbio.1000614-LagierTourenne1">[37]</xref>,
                    were not required for toxicity (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>, construct 1–501). Indeed, 1–501 was slightly
                    more toxic than full-length FUS (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>). This finding is consistent with the severe ALS phenotype
                    linked to FUS R495X <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>. Similar to TDP-43, the prion-like domain of FUS was
                    required but not sufficient for toxicity (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>, compare constructs 1–526,
                    1–168, 1–269, and 267–526). As for aggregation, most of the
                    N-terminal prion-like domain of FUS (amino acids 1–239) was needed for
                    toxicity (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>, compare
                    constructs 1–501, 50–526, and 100–526) and larger N-terminal
                    deletions were not toxic (<xref ref-type="fig" rid="pbio-1000614-g003">Figure
                        3D</xref>, compare constructs 165–526, 267–526, 285–526,
                    and 368–526). However, unlike TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>, adding back the RRM to
                    the prion-like domain did not restore toxicity (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>, construct 1–373). Rather,
                    for toxicity the RRM and the first RGG domain were required in addition to the
                    prion-like domain (<xref ref-type="fig" rid="pbio-1000614-g003">Figure
                    3D</xref>, compare constructs 1–373 and 1–422). However, 1–422
                    was not as toxic as full-length FUS, and additional C-terminal sequences were
                    required to confer full toxicity (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3D</xref>, compare constructs 1–422, 1–453, and
                    1–501). These findings are consistent with a pathogenic FUS truncation
                    mutant (amino acids 1–466) connected with sporadic ALS <xref ref-type="bibr" rid="pbio.1000614-DejesusHernandez1">[68]</xref>.</p>
                <p>Next, we tested whether FUS must bind RNA and aggregate to be toxic in yeast.
                    Thus, we mutated conserved phenylalanine residues within the FUS RRM to leucine
                    (Phe305, 341, 359, 368Leu) that would disrupt RNA binding <xref ref-type="bibr" rid="pbio.1000614-Buratti1">[69]</xref>. These mutations were
                    sufficient to mitigate toxicity but had no effect on cytoplasmic aggregation
                        (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3E,F</xref>). Analogous
                    mutations to the RRMs of TDP-43 disable RNA binding <xref ref-type="bibr" rid="pbio.1000614-Buratti1">[69]</xref> and also mitigate toxicity
                    in yeast <xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>.
                    Taken together, these data indicate that the N-terminal prion-like domain, first
                    RGG domain, and RRM (likely via RNA binding) of FUS contribute to toxicity.
                    Identifying the specific RNA targets of FUS (for example, see <xref ref-type="bibr" rid="pbio.1000614-Kim1">[70]</xref>) will provide
                    key insights into mechanisms of toxicity associated with FUS aggregation in
                    disease. Overall, compared to TDP-43, FUS aggregation and toxicity in yeast is a
                    more complex multi-domain process. Importantly, our studies define the
                    prion-like FUS N-terminal domain and first RGG domain as potential targets to
                    prevent or reverse FUS aggregation and toxicity.</p>
            </sec>
            <sec id="s2f">
                <title>FUS Is Intrinsically Aggregation Prone</title>
                <p>To determine whether FUS is intrinsically prone to aggregation, we purified
                    bacterially expressed recombinant FUS as a soluble protein under native
                    conditions. However, expression of various constructs including N- and
                    C-terminal His-tagged FUS in various bacterial strains failed to yield soluble
                    protein. The solubility of various proteins, including TDP-43 and polyglutamine,
                    can be enhanced by the addition of a glutathione-S-transferase (GST) tag <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Scherzinger1">[41]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Smith1">[71]</xref>. Even so,
                    FUS bearing a C-terminal GST-tag was also insoluble in various bacterial
                    strains. Fortunately, an N-terminal GST-tag allowed FUS to be purified as a
                    soluble protein under native conditions. GST-FUS remained soluble for extended
                    periods and was competent to bind RNA in mobility shift assays (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5A</xref>). To study FUS
                    aggregation, we added tobacco etch virus (TEV) protease to cleave at a single
                    unique site and specifically remove the N-terminal GST-tag (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5B</xref>). This strategy has been utilized
                    successfully to study the aggregation of extremely aggregation-prone proteins,
                    including polyglutamine <xref ref-type="bibr" rid="pbio.1000614-Scherzinger1">[41]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Tam1">[43]</xref>. Upon addition of TEV protease, FUS aggregated
                    extremely rapidly (<xref ref-type="fig" rid="pbio-1000614-g005">Figure
                    5C</xref>). By contrast, GST-FUS remained predominantly soluble (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5C</xref>). Under identical
                    conditions neither GST nor TEV protease aggregated (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5C</xref>). Aggregation was dependent on FUS
                    concentration in three ways: at higher FUS concentrations, the maximum amplitude
                    or endpoint of turbidity was increased, the length of lag phase was reduced and
                    the rate of aggregation during assembly phase was accelerated (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5C</xref>). Sedimentation
                    analysis revealed that after addition of TEV protease, FUS entered the pellet
                    fraction, whereas GST-FUS remained largely soluble (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5D</xref>). Indeed, there was very little FUS
                    in the supernatant fraction at any time, indicating that aggregation occurred
                    rapidly after proteolytic liberation of FUS from GST (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5D</xref>). The aggregates formed by FUS did
                    not react with the amyloid-diagnostic dye Thioflavin-T and were SDS-soluble, in
                    contrast to those formed by NM, the prion domain of yeast prion protein Sup35
                        (<xref ref-type="fig" rid="pbio-1000614-g005">Figure 5E,F</xref>). Thus,
                    pure FUS forms aggregates that are likely non-amyloid in nature, just like the
                    aggregated species of FUS observed in ALS and FTLD patients <xref ref-type="bibr" rid="pbio.1000614-ChenPlotkin1">[5]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Forman1">[72]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Kwong2">[73]</xref>.</p>
                <fig id="pbio-1000614-g005" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g005</object-id>
                    <label>Figure 5</label>
                    <caption>
                        <title>FUS is intrinsically aggregation prone.</title>
                        <p>(A) RNA mobility shift experiments. <sup>32</sup>P-labelled FUS RNA probe
                            (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>) was
                            incubated in the presence or absence of increasing amounts of GST-FUS or
                            GST and resolved on a native gel to observe free and bound RNA species.
                            (B) Schematic of FUS aggregation assay. TEV protease is added to remove
                            the GST tag and untagged FUS aggregation kinetics are followed over 90
                            min. (C) GST-FUS or GST (2.5–5 µM) was incubated in the
                            presence or absence of TEV protease at 22°C for 0–90 min.
                            Turbidity measurements were taken every minute to assess the extent of
                            aggregation. Values represent means
                            (<italic>n</italic> = 3). (D) GST-FUS (5 µM)
                            was incubated in the presence or absence of TEV protease at 22°C for
                            0–60 min. At the indicated times, reactions were processed for
                            sedimentation analysis. Pellet and supernatant fractions were resolved
                            by SDS-PAGE and stained with Coomassie Brilliant Blue. A representative
                            gel is shown. Note that cleaved FUS partitions mostly to the pellet
                            fraction, whereas GST-FUS remains in the supernatant (SN) fraction. The
                            amount of GST-FUS or FUS in the pellet fraction was determined by
                            densitometry in comparison to known quantities of GST-FUS or FUS. Values
                            represent means ± SEM
                            (<italic>n</italic> = 4). (E) FUS (5 µM) was
                            aggregated as in (C) for 60 min and processed for Thioflavin-T (ThT)
                            fluorescence and compared to the ThT fluorescence of assembled Sup35-NM
                            fibers (5 µM monomer). Values represent means ± SEM
                                (<italic>n</italic> = 3). (F) FUS (5 µM)
                            was aggregated as in (C) for 60 min. The amount of SDS-resistant FUS was
                            then determined and compared to the amount of SDS-resistant Sup35-NM in
                            assembled Sup35-NM fibers (5 µM monomer). Values represent means
                            ± SEM (<italic>n</italic> = 3).</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g005" xlink:type="simple"/>
                </fig>
                <p>The rapid aggregation of FUS occurred without agitation of the reaction (<xref ref-type="fig" rid="pbio-1000614-g005">Figures 5C</xref>, <xref ref-type="fig" rid="pbio-1000614-g006">6A</xref>). Remarkably, under these
                    conditions, even TDP-43 did not aggregate (<xref ref-type="fig" rid="pbio-1000614-g006">Figure 6A</xref>). TDP-43 requires many hours to
                    aggregate unless the reaction is agitated <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>. Agitation had little
                    effect on the rate of FUS aggregation (<xref ref-type="fig" rid="pbio-1000614-g006">Figure 6A,B</xref>), indicating that under these
                    conditions FUS aggregation is energetically favorable. Even when the reaction
                    was agitated, TDP-43 aggregation was still considerably slower than FUS
                    aggregation (<xref ref-type="fig" rid="pbio-1000614-g006">Figure 6B</xref>). In
                    particular, the lag period prior to aggregation was longer for TDP-43 than for
                    FUS (<xref ref-type="fig" rid="pbio-1000614-g006">Figure 6B</xref>). This
                    extended lag period was not due to different rates of FUS or TDP-43 cleavage by
                    TEV protease, which were extremely similar (unpublished data). Rather,
                    nucleation of aggregation is apparently more rate limiting for TDP-43 than it is
                    for FUS. Collectively, these data suggest that, even in comparison to TDP-43,
                    FUS is extremely aggregation prone. These data are also in keeping with the
                    higher prion-like domain score of FUS compared to TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>. In vivo, such rapid FUS
                    aggregation is most likely precluded by the proteostasis network <xref ref-type="bibr" rid="pbio.1000614-Powers1">[46]</xref>. However,
                    FUS likely escapes these safeguards in disease situations where proteostatic
                    buffers may have declined with age or because of environmental triggers.
                    Irrespective of the factors that may elicit FUS aggregation in disease, pure
                    protein assays akin to the one we report here have been powerful tools to
                    dissect the mechanisms underlying the aggregation of various disease-connected
                    proteins, including TDP-43 and polyglutamine <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Scherzinger1">[41]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Tam1">[43]</xref>.</p>
                <fig id="pbio-1000614-g006" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g006</object-id>
                    <label>Figure 6</label>
                    <caption>
                        <title>FUS aggregates more rapidly than TDP-43 in vitro.</title>
                        <p>(A) GST-FUS or GST-TDP-43 (2.5 or 5 µM) was incubated in the
                            presence of TEV protease at 22°C for 0–90 min. Turbidity
                            measurements were taken every minute to assess the extent of
                            aggregation. A dataset representative of three replicates is shown. (B)
                            GST-FUS or GST-TDP-43 (2.5 or 5 µM) was incubated in the presence
                            of TEV protease at 22°C with agitation (700 rpm) for 0–90 min.
                            The extent of aggregation was determined by turbidity. A dataset
                            representative of three replicates is shown.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g006" xlink:type="simple"/>
                </fig>
            </sec>
            <sec id="s2g">
                <title>The Prion-Like Domain and First RGG Domain of FUS Are Important for
                    Aggregation</title>
                <p>Next, we determined how the N- and C-terminal domains of FUS contribute to
                    aggregation of the pure protein. Consistent with observations in yeast (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B</xref>), deletion of the
                    N-terminal prion-like domain of FUS yielded protein (267–526) that
                    remained soluble over the time course of the assay as determined by turbidity
                    and sedimentation analysis (<xref ref-type="fig" rid="pbio-1000614-g007">Figure
                        7A,B</xref>). These data suggest that the prion-like domain of FUS is
                    required for aggregation. Curiously, however, but also consistent with
                    observations in yeast, a protein bearing the prion-like domain and adjacent
                    C-terminal sequences (1–373) did not aggregate under these conditions
                        (<xref ref-type="fig" rid="pbio-1000614-g007">Figure 7A,B</xref>). Even at
                    higher concentrations (20 µM), neither FUS 267–526 nor FUS
                    1–373 aggregated. Moreover, if the reaction was subsequently agitated at
                    700 rpm for an additional 60 min neither FUS 267–526 nor FUS 1–373
                    aggregated.</p>
                <fig id="pbio-1000614-g007" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g007</object-id>
                    <label>Figure 7</label>
                    <caption>
                        <title>Defining the domain requirements for the aggregation of pure
                            FUS.</title>
                        <p>(A) GST-FUS, GST-FUS 267–526, GST-FUS 1–373 (2.5 µM or
                            5 µM), or GST-FUS 1–422 (2.5 µM, 5 µM, or 20
                            µM) were incubated in the presence of TEV protease at 22°C for
                            0–90 min. Turbidity measurements were taken every minute to assess
                            the extent of aggregation. A dataset representative of three replicates
                            is shown. (B) GST-FUS, GST-FUS 267–526, GST-FUS 1–373, or
                            GST-FUS 1–422 (5 µM) were incubated in the presence or
                            absence of TEV protease at 22°C for 0–60 min. At the indicated
                            times, reactions were processed for sedimentation analysis. Pellet and
                            supernatant fractions were resolved by SDS-PAGE and stained with
                            Coomassie Brilliant Blue. The amount of GST-FUS or FUS in the pellet
                            fraction was determined by densitometry in comparison to known
                            quantities of GST-FUS or FUS. Values represent means ± SEM
                                (<italic>n</italic> = 3).</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g007" xlink:type="simple"/>
                </fig>
                <p>Next, we tested FUS 1–422, a minimal fragment of FUS able to confer
                    toxicity <italic>and</italic> aggregation in yeast (<xref ref-type="fig" rid="pbio-1000614-g003">Figure 3B,D</xref>). FUS 1–422 aggregated with
                    similar kinetics to full-length FUS as determined by sedimentation analysis
                        (<xref ref-type="fig" rid="pbio-1000614-g007">Figure 7B</xref>). Curiously,
                    however, at these concentrations (2.5–5 µM) FUS 1–422
                    aggregates did yield a signal by turbidity (<xref ref-type="fig" rid="pbio-1000614-g007">Figure 7A</xref>). Higher concentrations of FUS
                    1–422 (20 µM) were required to generate aggregates detectable by
                    turbidity (<xref ref-type="fig" rid="pbio-1000614-g007">Figure 7A</xref>). These
                    concentration differences in the turbidity measurements for full-length FUS and
                    FUS 1–422 suggest that there are large disparities in the sizes of the
                    aggregates formed by these two proteins because turbidity readily detects large
                    but not small aggregates <xref ref-type="bibr" rid="pbio.1000614-Frankenfield1">[74]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Andreu1">[76]</xref>. A similar finding has been
                    made with PrP, where deletion of the N-terminal domain reduces the formation of
                    larger turbid aggregates, without affecting the formation of smaller aggregates
                        <xref ref-type="bibr" rid="pbio.1000614-Frankenfield1">[74]</xref>. These data suggest that the C-terminal region,
                    comprising amino acids 423–526, while dispensable for aggregation per se
                        (<xref ref-type="fig" rid="pbio-1000614-g007">Figure 7B</xref>), promotes
                    the formation of large macroscopic aggregates of FUS that are detected by
                    turbidity (<xref ref-type="fig" rid="pbio-1000614-g007">Figure 7A</xref>).</p>
            </sec>
            <sec id="s2h">
                <title>Pure FUS Aggregates Resemble FUS Aggregates in Degenerating Neurons of ALS
                    Patients</title>
                <p>Electron microscopy (EM) confirmed that pure FUS 1–373 and FUS
                    267–526 do not form aggregated species in isolation (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8A,B</xref>). Rather, these proteins persist
                    as small oligomeric particles (<xref ref-type="fig" rid="pbio-1000614-g007">Figure 8A,B</xref>). In the absence of TEV protease, both FUS and FUS
                    1–422 did not aggregate but remained as small oligomeric species (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8C,D</xref>). After addition
                    of TEV protease, FUS and FUS 1–422 rapidly populated oligomeric forms,
                    which adopted a pore-like conformation reminiscent of pathological oligomers
                    formed by TDP-43, α-synuclein, and Aβ42 (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8E</xref>) <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Lashuel1">[42]</xref>. FUS 1–422 rapidly
                    aggregated in an ordered manner to generate separated filamentous structures
                        (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8C</xref>). Likewise,
                    full-length FUS also rapidly formed linear polymers (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8D</xref>). In both cases, these filaments
                    were approximately 15–20 nm in diameter and could extend several
                    micrometers in length (<xref ref-type="fig" rid="pbio-1000614-g008">Figure
                        8C,D</xref>). Consistent with turbidity measurements, the polymers formed by
                    full-length FUS became tangled and stacked against one another to form extremely
                    large and complex macroscopic networks (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8D,F</xref>). FUS 1–422 polymers
                    remained more separated with limited lateral interaction (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8C,F</xref>). These ultrastructural
                    observations explain why FUS 1–422 aggregates are more difficult to detect
                    by turbidity.</p>
                <fig id="pbio-1000614-g008" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g008</object-id>
                    <label>Figure 8</label>
                    <caption>
                        <title>Pure FUS aggregates resemble FUS aggregates in degenerating motor
                            neurons of ALS patients.</title>
                        <p>(A, B) GST-FUS 267–526 (2.5 µM) (A) or GST-FUS 1–373
                            (2.5 µM) (B) were incubated in the presence of TEV protease at
                            22°C for 0 or 60 min and processed for EM. Bar, 500 nm. (C) GST-FUS
                            1–422 (2.5 µM) was incubated in the absence or presence of
                            TEV protease at 22°C for 0–60 min. At the indicated times,
                            reactions were processed for EM. In the absence of TEV protease, very
                            little aggregation occurs. In the presence of TEV protease, pore-shaped
                            oligomers (arrows) and filamentous polymers (arrowheads) rapidly
                            assemble. At 60 min, the filamentous structures stay well separated but
                            are sometimes associated with smaller FUS 1–422 oligomers. Bar,
                            500 nm. (D) GST-FUS (2.5 µM) was incubated in the absence or
                            presence of TEV protease at 22°C for 0–60 min. At the
                            indicated times, reactions were processed for EM. In the absence of TEV
                            protease, very little aggregation occurs. In the presence of TEV
                            protease, pore-shaped oligomers (arrows) and filamentous polymers
                            (arrowheads) rapidly assemble. The filamentous structures often form
                            higher order network structures by 30 and 60 min. (E) Gallery of
                            pore-shaped FUS 1–422 oligomers formed after 30 min and
                            pore-shaped FUS oligomers formed after 10 min. Bar, 50 nm. (F) Lower
                            magnification view of filamentous FUS 1–422 and FUS aggregates
                            formed after 60 min in the presence of TEV protease. Note that FUS
                            aggregates accumulate as larger networks that conglomerate into large
                            aggregates, whereas FUS 1–422 filaments remain well separated.
                            This difference in morphology likely explains why FUS aggregates
                            generate a larger turbidity signal than FUS 1–422 aggregates. Bar,
                            500 nm.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g008" xlink:type="simple"/>
                </fig>
                <p>Importantly, the filamentous structures formed by both FUS and FUS 1–422
                    bear striking resemblance to the FUS aggregates observed in the degenerating
                    motor neurons of ALS patients <xref ref-type="bibr" rid="pbio.1000614-Huang1">[21]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Baumer1">[77]</xref>. In motor neurons of patients with juvenile ALS, FUS
                    forms filamentous aggregates with a uniform diameter of 15–20 nm, which
                    are often associated with small granules <xref ref-type="bibr" rid="pbio.1000614-Huang1">[21]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Baumer1">[77]</xref>. The filamentous structures
                    formed by FUS and FUS 1–422 in isolation (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8C,D,F</xref>) are extremely similar to those
                    observed in spinal motor neurons in <xref ref-type="fig" rid="pbio-1000614-g003">Figure 3C</xref> of Huang et al. <xref ref-type="bibr" rid="pbio.1000614-Huang1">[21]</xref>. In vitro, small FUS or FUS
                    1–422 oligomers are often found clustered up against the filamentous
                    structures (<xref ref-type="fig" rid="pbio-1000614-g008">Figure 8C,D,F</xref>).
                    These oligomers may correspond to the granular structures observed in
                    association with filamentous FUS aggregates in motor neurons of ALS patients
                        <xref ref-type="bibr" rid="pbio.1000614-Huang1">[21]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Baumer1">[77]</xref>. In sum,
                    these observations suggest that in isolation FUS is intrinsically capable of
                    forming the aggregated structures observed in motor neurons of ALS patients.</p>
                <p>Taken together, the biochemical and EM data suggest that FUS aggregation requires
                    multiple domains in both N- and C-terminal regions. Specifically, determinants
                    in the N-terminal prion-like domain (1–239) and the first C-terminal RGG
                    domain (374–422) are essential for the formation of filamentous
                    structures. More C-terminal regions (423–526) are then required for the
                    formation of large macroscopic aggregates detected by turbidity.</p>
            </sec>
            <sec id="s2i">
                <title>ALS-Linked FUS Mutations Do Not Affect Aggregation or Toxicity</title>
                <p>FUS mutations have been connected with some familial and sporadic ALS cases <xref ref-type="bibr" rid="pbio.1000614-LagierTourenne1">[37]</xref>. We
                    next used the yeast model to test the effects of some of these mutations on FUS
                    aggregation and toxicity (<xref ref-type="fig" rid="pbio-1000614-g009">Figure
                        9A</xref>). For TDP-43, we have used this approach to determine that
                    ALS-linked mutations increase TDP-43 aggregation and toxicity <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>. This
                    increased toxicity of mutant TDP-43 in yeast has been supported by independent
                    studies in mammalian cells and animal models <xref ref-type="bibr" rid="pbio.1000614-Sreedharan1">[9]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Ritson1">[78]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Barmada1">[80]</xref>. To assess aggregation, we
                    expressed YFP-tagged fusions of WT FUS and 12 different ALS-linked FUS mutants
                    in yeast. These FUS variants were all expressed at similar levels (<xref ref-type="fig" rid="pbio-1000614-g009">Figure 9B</xref>). Moreover,
                    comparison of the number of proportion of yeast cells with three or more foci
                    revealed that ALS-linked FUS mutations do not promote FUS aggregation in yeast
                        (<xref ref-type="fig" rid="pbio-1000614-g009">Figure 9C,D</xref>). Indeed,
                    FUS aggregation was slightly reduced in various ALS-linked FUS variants,
                    although this reduction was not statistically significant (<xref ref-type="fig" rid="pbio-1000614-g009">Figure 9C,D</xref>). Consistent with these
                    observations, the ALS-linked FUS variants—H517Q, R521C, and
                    R521G—aggregated with very similar kinetics to WT in pure protein
                    aggregation assays, although aggregation was slightly retarded in these mutants
                        (<xref ref-type="fig" rid="pbio-1000614-g009">Figure 9E</xref>).
                    Collectively, these data suggest that this set of ALS-linked FUS mutations,
                    clustered in the extreme C-terminal region of FUS, do not promote FUS
                    aggregation per se. Furthermore, we did not observe any significant difference
                    in toxicity between WT and ALS-linked FUS variants (<xref ref-type="fig" rid="pbio-1000614-g009">Figure 9F</xref>). These data are in contrast to
                    TDP-43, where several ALS-linked mutations promote aggregation and toxicity
                        <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>.</p>
                <fig id="pbio-1000614-g009" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g009</object-id>
                    <label>Figure 9</label>
                    <caption>
                        <title>The effect of ALS-linked FUS mutations on aggregation and
                            toxicity.</title>
                        <p>(A) Diagram indicating disease-associated FUS mutations tested in this
                            study. (B) Immunoblot showing equivalent expression levels of WT or
                            mutant FUS. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as
                            a loading control. (C) ALS-linked mutations did not significantly affect
                            FUS aggregation in yeast. (D) The effect of ALS-linked FUS mutations on
                            aggregation in yeast cells was quantified by counting the number of
                            cells containing &gt;3 FUS-YFP foci (as in <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref> for TDP-43).
                            Values represent means ± SEM (<italic>n</italic>≥3, at least
                            200 cells per sample). As for FUS toxicity, these ALS-linked mutations
                            did not significantly enhance FUS aggregation, in contrast to TDP-43
                            mutations, which did increase aggregation <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>. (E) GST-FUS,
                            GST-FUS H517Q, GST-FUS R521H, or GST-FUS R521C (2.5 µM) was
                            incubated in the presence of TEV protease at 22°C for 0–90
                            min. Turbidity measurements were taken every minute to assess the extent
                            of aggregation. A dataset representative of three replicates is shown.
                            (F) Spotting assay to compare the toxicity of WT and mutant FUS. Serial
                            dilutions of yeast cells transformed with galactose-inducible empty
                            vector, WT, or mutant FUS-YFP constructs. Transformants were spotted on
                            glucose (non-inducing) or galactose (inducing) containing agar plates,
                            and growth was assessed after 3 d. In contrast to TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>,
                            the ALS-linked FUS mutations did not enhance FUS toxicity in yeast.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g009" xlink:type="simple"/>
                </fig>
                <p>It seems likely that in disease, these C-terminal ALS-linked FUS mutations
                    promote pathological events that are primarily upstream of aggregation and
                    toxicity. One obvious upstream event is mislocalization to the cytoplasm.
                    Indeed, studies in mammalian cells suggest that ALS-linked FUS mutations can
                    disrupt nuclear import <xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. In yeast, FUS is already localized predominantly to
                    the cytoplasm (<xref ref-type="fig" rid="pbio-1000614-g001">Figures 1C</xref>,
                        <xref ref-type="fig" rid="pbio-1000614-g009">9C</xref>), so in this setting
                    the ALS-linked mutants are no more toxic than WT (<xref ref-type="fig" rid="pbio-1000614-g009">Figure 9C,D,F</xref>). Thus, even though FUS and
                    TDP-43 are related RNA-binding proteins, the mechanisms by which ALS-linked
                    mutations contribute to disease might be different for each protein <xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>.
                    Consequently, different therapeutic strategies might be needed for FUS and
                    TDP-43 proteinopathies. To examine this idea further, we performed two
                    genome-wide screens in yeast to (1) identify genetic modifiers of FUS toxicity
                    and (2) determine whether genetic modifiers of FUS toxicity also affected TDP-43
                    toxicity.</p>
            </sec>
            <sec id="s2j">
                <title>A Yeast Genome-Wide Overexpression Screen Identifies Modifiers of FUS
                    Toxicity</title>
                <p>Of the many experimental benefits afforded by the yeast system <xref ref-type="bibr" rid="pbio.1000614-Gitler1">[13]</xref>, the chief
                    advantage is the ability to perform high-throughput genetic modifier screens.
                    Therefore, to provide insight into cellular mechanisms underpinning FUS
                    toxicity, we performed two unbiased yeast genetic modifier screens to identify
                    genes that enhance or suppress FUS toxicity. We reasoned that the genes
                    identified by these screens would illuminate cellular pathways perturbed by
                    abnormal FUS accumulation and suggest potential novel targets for therapeutic
                    intervention. Similar approaches have elucidated modifiers of the
                    Parkinson's disease protein α-synuclein <xref ref-type="bibr" rid="pbio.1000614-Cooper1">[39]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Gitler2">[40]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Willingham1">[45]</xref>,<xref ref-type="bibr" rid="pbio.1000614-YegerLotem1">[81]</xref>, a mutant form of the
                    Huntington's disease protein huntingtin <xref ref-type="bibr" rid="pbio.1000614-Giorgini1">[44]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Willingham1">[45]</xref>, and more recently, the
                    ALS protein TDP-43 (<xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>; A. Elden and A.D.G. unpublished). In the latter
                    example, the yeast system allowed definition of a common genetic risk factor for
                    ALS in humans <xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>.</p>
                <p>First, we performed a plasmid overexpression screen (<xref ref-type="fig" rid="pbio-1000614-g010">Figure 10A</xref>). We individually transformed
                    5,500 yeast genes, which comprise the Yeast FLEXGene plasmid overexpresssion
                    library <xref ref-type="bibr" rid="pbio.1000614-Hu1">[82]</xref>, into
                    a yeast strain harboring an integrated galactose-inducible FUS expression
                    plasmid. We then identified yeast genes that suppressed or enhanced FUS toxicity
                    when overexpressed (<xref ref-type="fig" rid="pbio-1000614-g010">Figure
                        10B</xref>). We repeated the screen three independent times and only
                    selected hits that reproduced all three times. Genes from the screen that
                    enhanced FUS toxicity, but also caused toxicity when overexpressed in WT yeast
                    cells, were eliminated because these were unlikely to be specific to FUS. We
                    also eliminated certain genes involved in carbohydrate metabolism or
                    galactose-regulated gene expression because, based on previous screens with this
                    library, we have found that they simply affect expression from the
                    galactose-regulated promoter and are unlikely to relate to FUS biology. Indeed,
                    most of these were also recovered as hits in screens with a galactose-regulated
                    toxic huntingtin, α-syn or TDP-43 (<xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Cooper1">[39]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Giorgini1">[44]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Willingham1">[45]</xref>,<xref ref-type="bibr" rid="pbio.1000614-YegerLotem1">[81]</xref>; A. Elden and A.D.G.
                    unpublished). Finally, we retested 10 random plasmids (six suppressors and four
                    enhancers) by transforming them into a fresh yeast strain harboring the
                    integrated FUS expression plasmid and performed spotting assays and all 10 of
                    these were confirmed (<xref ref-type="supplementary-material" rid="pbio.1000614.s005">Figure S5</xref>).</p>
                <fig id="pbio-1000614-g010" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g010</object-id>
                    <label>Figure 10</label>
                    <caption>
                        <title>Yeast plasmid overexpression screen identifies suppressors and
                            enhancers of FUS toxicity.</title>
                        <p>(A) Schematic of yeast genetic screen. Yeast cells harboring an
                            integrated galactose-inducible FUS-YFP cassette were individually
                            transformed with a library of 5,500 yeast open reading frames (ORFs) and
                            spotted onto galactose plates to induce expression of FUS and each gene
                            from the library. (B) A representative plate from the yeast screen. Each
                            spot represents a yeast strain expressing FUS along with one gene from
                            the library. Examples of genes that suppressed FUS toxicity (improved
                            growth) are indicated by green arrows and enhancers of toxicity
                            (inhibited growth) are indicated by red arrows. (C) A histogram
                            indicating the functional categories of genes enriched as hits in the
                            screen compared to the yeast genome. Genes involved in transcription and
                            RNA metabolism were significantly overrepresented as hits in the screen
                            (indicated by *). (D) Human homologs of two FUS toxicity modifier
                            genes from the yeast screen, FBXW7 and EIF4A1, suppressed FUS toxicity
                            in human cells (HEK293T), when co-transfected with FUS or ALS-linked FUS
                            mutants, R521C and R521H. Cell viability was assessed by MTT assay.
                            Values represent means ± S.D.
                            (<italic>n</italic> = 3).</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g010" xlink:type="simple"/>
                </fig>
                <p>Following the above validation and filtering procedures, we identified 24 genes
                    that suppressed and 10 genes that enhanced FUS toxicity when overexpressed
                        (<xref ref-type="table" rid="pbio-1000614-t001">Table 1</xref>). The largest
                    functional class enriched in the screen included RNA-binding proteins and
                    proteins involved in RNA metabolism (<xref ref-type="fig" rid="pbio-1000614-g010">Figure 10C</xref>). Thus, RNA metabolic pathways
                    play a key role in FUS pathogenesis. Importantly, of 71 genes from this library
                    that modify α-synuclein toxicity in yeast <xref ref-type="bibr" rid="pbio.1000614-Cooper1">[39]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Gitler2">[40]</xref>, only two (Cdc4 and Tps3)
                    affected FUS toxicity. This lack of overlap underscores the specificity of the
                    screen for FUS biology and pathobiology. Moreover, this specificity indicates
                    that the screen does not simply identify generic cellular responses to misfolded
                    proteins. Even more remarkably, out of the 40 yeast genes that we have found to
                    modify TDP-43 toxicity when overexpressed (<xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref> and A. Elden and A.D.G.
                    unpublished observations), only two (Fmp48 and Tis11) affected FUS toxicity.
                    Thus, despite being similar RNA-binding proteins, the mechanisms by which FUS
                    and TDP-43 contribute to disease are likely to be very different.</p>
                <table-wrap id="pbio-1000614-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pbio.1000614.t001</object-id><label>Table 1</label><caption>
                        <title>Yeast genes that suppress or enhance FUS toxicity when
                            overexpressed.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pbio-1000614-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.t001" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Effect</td>
                                <td align="left" colspan="1" rowspan="1">Gene</td>
                                <td align="left" colspan="1" rowspan="1">Human Homolog</td>
                                <td align="left" colspan="1" rowspan="1">Function</td>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">CDC4</td>
                                <td align="left" colspan="1" rowspan="1">FBXW7</td>
                                <td align="left" colspan="1" rowspan="1">F-box protein required for G1/S and G2/M
                                    transition</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">CUE2</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein of unknown function</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">ECM32</td>
                                <td align="left" colspan="1" rowspan="1">UPF1</td>
                                <td align="left" colspan="1" rowspan="1">DNA dependent ATPase/DNA helicase, involved in
                                    modulating translation termination</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">EDC3</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Non-essential conserved protein of unknown
                                    function, plays a role in mRNA decapping</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">FHL1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Putative transcriptional regulator, required for
                                    rRNA processing</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">FMP48</td>
                                <td align="left" colspan="1" rowspan="1">STK36</td>
                                <td align="left" colspan="1" rowspan="1">Mitochondrial protein of unknown function</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">NAM8</td>
                                <td align="left" colspan="1" rowspan="1">TRNAU1AP</td>
                                <td align="left" colspan="1" rowspan="1">RNA binding protein, component of the U1 snRNP
                                    protein</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">PAB1</td>
                                <td align="left" colspan="1" rowspan="1">PABPC4</td>
                                <td align="left" colspan="1" rowspan="1">Poly(A) binding protein, part of the 3′-end
                                    RNA-processing complex, involved in stress granule
                                    formation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">PIG1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Putative targeting subunit for the type-1 protein
                                    phosphatase Glc7p</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">SBP1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Nucleolar single-strand nucleic acid binding
                                    protein, associates with small nuclear RNAs</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">SEY1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein of unknown function, contains two predicted
                                    GTP-binding motifs</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">SKO1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Basic leucine zipper (bZIP) transcription factor of
                                    the ATF/CREB family</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">SYN8</td>
                                <td align="left" colspan="1" rowspan="1">STX8</td>
                                <td align="left" colspan="1" rowspan="1">Endosomal SNARE related to mammalian syntaxin
                                    8</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">TIF2</td>
                                <td align="left" colspan="1" rowspan="1">EIF4A1</td>
                                <td align="left" colspan="1" rowspan="1">Translation initiation factor eIF4A, RNA helicase
                                    that couples ATPase activity to RNA binding and unwinding,
                                    involved in stress granule formation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">TIF3</td>
                                <td align="left" colspan="1" rowspan="1">EIF4B</td>
                                <td align="left" colspan="1" rowspan="1">Translation initiation factor eIF-4B, has RNA
                                    annealing activity, contains an RNA recognition motif and binds
                                    to single-stranded RNA, involved in stress granule
                                    formation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">TIS11</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">mRNA-binding protein involved in iron
                                    homeostasis</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">TPS3</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Regulatory subunit of trehalose-6-phosphate
                                    synthase/phosphatase complex</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">TRM11</td>
                                <td align="left" colspan="1" rowspan="1">TRMT11</td>
                                <td align="left" colspan="1" rowspan="1">Catalytic subunit of an adoMet-dependent tRNA
                                    methyltransferase complex</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">VHR1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Transcriptional activator</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YHR151C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Unknown</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YOR062C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Unknown</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YPR147C</td>
                                <td align="left" colspan="1" rowspan="1">C2orf43</td>
                                <td align="left" colspan="1" rowspan="1">Unknown</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">ZDS2</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein that interacts with silencing proteins at
                                    the telomere, involved in transcriptional silencing</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">CLB2</td>
                                <td align="left" colspan="1" rowspan="1">CCNB1</td>
                                <td align="left" colspan="1" rowspan="1">B-type cyclin involved in cell cycle
                                    progression</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">CST6</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Basic leucine zipper (bZIP) transcription factor of
                                    the ATF/CREB family</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">FZO1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Mitochondrial integral membrane protein involved in
                                    mitochondrial fusion and maintenance of the mitochondrial
                                    genome</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">HOF1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Bud neck-localized protein required for
                                    cytokinesis</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">INM1</td>
                                <td align="left" colspan="1" rowspan="1">IMPA1</td>
                                <td align="left" colspan="1" rowspan="1">Inositol monophosphatase</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">IRC3</td>
                                <td align="left" colspan="1" rowspan="1">EIF4A3</td>
                                <td align="left" colspan="1" rowspan="1">Putative RNA helicase of the DEAH/D-box family</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">NAB3</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Single stranded RNA binding protein, required for
                                    termination of non-poly(A) transcripts and efficient
                                    splicing</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">PET111</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Specific translational activator for the COX2 mRNA,
                                    located in the mitochondrial inner membrane</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">TRM5</td>
                                <td align="left" colspan="1" rowspan="1">TRMT5</td>
                                <td align="left" colspan="1" rowspan="1">tRNA methyltransferase</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">YMR166C</td>
                                <td align="left" colspan="1" rowspan="1">SLC25A26</td>
                                <td align="left" colspan="1" rowspan="1">Predicted transporter of the mitochondrial inner
                                    membrane</td>
                            </tr>
                        </tbody>
                    </table></alternatives></table-wrap>
                <p>Several of the yeast genes that modified FUS toxicity have human homologs. Thus,
                    pathways involved in FUS toxicity in yeast are likely conserved to man.
                    Interestingly, FUS has recently been shown to co-localize with stress granules
                    in transfected cells <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. Furthermore, cytoplasmic FUS-positive inclusions in
                    ALS and FTLD-U patients contain stress granule markers <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. Stress granules and
                    P-bodies are transient cytoplasmic structures containing RNAs and RNA binding
                    proteins, including translation initiation factors and the polyA-binding protein
                    (PABP-1), which are sites where cells sequester mRNAs, during situations of
                    stress, to inhibit translation initiation <xref ref-type="bibr" rid="pbio.1000614-Buchan3">[83]</xref>. Notably, we identified two
                    translation initiation factors (Tif2 and Tif3) and Pab1, the yeast homolog of
                    human PABP-1, which is involved in stress granule assembly in yeast, as
                    suppressors of FUS toxicity (<xref ref-type="table" rid="pbio-1000614-t001">Table 1</xref>). Thus, in addition to being markers of FUS-positive
                    inclusions in disease, stress granule components might play an important role in
                    mediating FUS toxicity. Approaches aimed at manipulating stress granule assembly
                    might be an effective therapeutic approach.</p>
            </sec>
            <sec id="s2k">
                <title>Overexpression Suppressors Isolated from Yeast Also Suppress FUS Toxicity in
                    Mammalian Cells</title>
                <p>As an initial step to extend our findings from yeast to mammalian cells, we
                    selected genes from our overexpression screen for further analysis in a
                    mammalian cell culture FUS toxicity model. We tested two distinct suppressor
                    genes, FBXW7 and EIF4A1, which are the human homologs of yeast Cdc4 and Tif2,
                    respectively (<xref ref-type="table" rid="pbio-1000614-t001">Table 1</xref>). We
                    transfected HEK293T cells with WT FUS or two ALS-linked FUS mutants, R521C and
                    R521H. The FUS mutants were more toxic than WT FUS, which only slightly reduced
                    viability (<xref ref-type="fig" rid="pbio-1000614-g010">Figure 10D</xref>).
                    Co-transfection with FBXW7 or EIF4A1 suppressed toxicity of WT FUS as well as
                    the ALS-linked FUS mutants (<xref ref-type="fig" rid="pbio-1000614-g010">Figure
                        10D</xref>). Similar results were observed in COS-7 cells (unpublished
                    data). The FUS toxicity modifier genes and pathways identified in our yeast
                    screens will have to be validated in neuronal cells and eventually animal
                    models. However, the ability of FBXW7 and EIF4A1 to suppress toxicity in human
                    cells, which are separated from yeast by ∼1 billion years of evolution,
                    provides evidence that highly conserved genetic interactions involving FUS,
                    discovered in yeast, can be highly relevant to mammalian cells.</p>
            </sec>
            <sec id="s2l">
                <title>A Yeast Genome-Wide Deletion Screen Identifies Modifiers of FUS
                    Toxicity</title>
                <p>To complement the yeast overexpression screen, we also performed a deletion
                    screen. The yeast genome contains ∼6,000 yeast genes and ∼4,850 of these
                    are non-essential <xref ref-type="bibr" rid="pbio.1000614-Giaever1">[84]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Goffeau1">[85]</xref>. We used synthetic genetic array (SGA) analysis <xref ref-type="bibr" rid="pbio.1000614-Tong1">[86]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Tong2">[87]</xref> to introduce
                    a FUS expression plasmid into each non-essential yeast deletion strain by mating
                        (<xref ref-type="fig" rid="pbio-1000614-g011">Figure 11A</xref>). Following
                    sporulation, we selectively germinated meiotic progeny containing both the FUS
                    plasmid and the gene deletion. We compared growth of each strain on glucose (FUS
                    expression “off”) to that on galactose (FUS expression
                    “on”). We identified some yeast deletions that enhanced FUS toxicity
                    (aggravating interaction) and others that suppressed toxicity (alleviating
                    interaction) (<xref ref-type="fig" rid="pbio-1000614-g011">Figure 11B</xref>).
                    As for the overexpression screen, we repeated the deletion screen three
                    independent times and only selected hits that reproduced all three times and
                    filtered out deletion strains that grew poorly on galactose-containing media,
                    even in the absence of FUS (using published data on yeast deletion strain
                    fitness on galactose and in house measurements of the yeast deletion collection
                    grown on galactose). Genetic interactions were further confirmed by random spore
                    analysis and the integrity of the deletions verified by sequencing the deletion
                    specific bar codes. We also independently confirmed six random hits by remaking
                    the deletions, confirming the deletions by PCR, and then transforming those
                    deletion strains with the FUS expression plasmid and performing spotting
                    assays.</p>
                <fig id="pbio-1000614-g011" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pbio.1000614.g011</object-id>
                    <label>Figure 11</label>
                    <caption>
                        <title>Yeast deletion screen identifies suppressors and enhancers of FUS
                            toxicity.</title>
                        <p>(A) Schematic of yeast deletion screen, based on <xref ref-type="bibr" rid="pbio.1000614-Tong2">[87]</xref>. The
                            galactose-inducible FUS expression construct (pAG416Gal-FUS-YFP) was
                            introduced into MATα strain Y7092 to generate the query strain. This
                            query strain was mated to the yeast haploid deletion collection of
                            non-essential genes (MATa, each gene deleted with KanMX cassette
                            (confers resistance to G418)). Mating, sporulation, and mutant selection
                            were performed using a Singer RoToR HDA (Singer Instruments, Somerset,
                            UK). Haploid mutants harboring the FUS expression plasmid were grown in
                            the presence of glucose (FUS expression “off”) or galactose
                            (FUS expression “on”). Following growth at 30°C for 2 d,
                            plates were photographed and colony sizes measured by ImageJ image
                            analysis software, based on <xref ref-type="bibr" rid="pbio.1000614-Collins1">[104]</xref>. (B) A
                            representative plate from the deletion screen. Left is glucose (deletion
                            alone, e.g. xxxΔ) and right is galactose (deletion + FUS
                            expression, e.g. xxxΔ + FUS). Each plate contains 384 different
                            strains pinned in duplicate (768 total). The red arrows point to an
                            aggravating genetic interaction (toxicity enhancer), in which the gene
                            deletion + FUS grows slower than FUS or the deletion alone. The
                            green arrows point to an alleviating genetic interaction (toxicity
                            suppressor), in which the gene deletion + FUS grows better than FUS
                            or the deletion alone. (C) A histogram indicating the functional
                            categories of genes enriched as hits in the screen compared to the yeast
                            genome. Genes involved in RNA metabolism, ribosome biogenesis, and
                            cellular stress responses were significantly overrepresented as hits in
                            the screen (indicated by *).</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.g011" xlink:type="simple"/>
                </fig>
                <p>We indentified 36 deletions that suppressed FUS toxicity and 24 that enhanced
                    toxicity (<xref ref-type="table" rid="pbio-1000614-t002">Table 2</xref>).
                    Deletions of yeast genes involved in RNA metabolic processes, ribosome
                    biogenesis, and cellular stress responses were enriched as hits (<xref ref-type="fig" rid="pbio-1000614-g011">Figure 11C</xref>). Many of these
                    genes have human homologs (<xref ref-type="table" rid="pbio-1000614-t002">Table
                        2</xref>). One interesting deletion suppressor was Sse1, a member of the
                    Hsp70 chaperone family, which promotes Sup35 prion formation <xref ref-type="bibr" rid="pbio.1000614-Sadlish1">[88]</xref> and might
                    also promote FUS aggregation. Two other notable deletion suppressors were Pub1
                    (TIAL1 in human) and Lsm7 (LSM7 in human), components of stress granules and
                    P-bodies, respectively. Furthermore, TIAL1 (and Pub1) contains a prion-like
                    domain <xref ref-type="bibr" rid="pbio.1000614-Alberti1">[32]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Gilks1">[89]</xref>, which can template the aggregation of the polyQ
                    protein huntingtin <xref ref-type="bibr" rid="pbio.1000614-Furukawa1">[90]</xref>, suggesting that FUS aggregation and cytoplasmic
                    sequestration might be templated by similar mechanisms <xref ref-type="bibr" rid="pbio.1000614-Doi1">[24]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Doi2">[91]</xref>. Again, as for the plasmid
                    overexpression screen, genetic manipulations that affect stress granule
                    components are sufficient to mitigate FUS toxicity. And, as for the
                    overexpression screen, there was little overlap between the FUS and TDP-43
                    modifier genes. In a broader sense, the collection of deletion suppressors of
                    FUS toxicity is an interesting class, because these could represent attractive
                    therapeutic targets for small molecule inhibitors or RNA interference. Taken
                    together, the genetic modifiers uncovered by the yeast overexpression and
                    deletion screens provide insight into the pathways affected by FUS. The way is
                    now open to develop therapeutic strategies that target these pathways.</p>
                <table-wrap id="pbio-1000614-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pbio.1000614.t002</object-id><label>Table 2</label><caption>
                        <title>Yeast genes that suppress or enhance FUS toxicity when
                            deleted.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pbio-1000614-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.t002" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Effect</td>
                                <td align="left" colspan="1" rowspan="1">Gene</td>
                                <td align="left" colspan="1" rowspan="1">Human Homolog</td>
                                <td align="left" colspan="1" rowspan="1">Function</td>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">ALF1</td>
                                <td align="left" colspan="1" rowspan="1">TBCB</td>
                                <td align="left" colspan="1" rowspan="1">Alpha-tubulin folding protein</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">BUD26</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">CGI121</td>
                                <td align="left" colspan="1" rowspan="1">TPRKB</td>
                                <td align="left" colspan="1" rowspan="1">Protein involved in telomere uncapping and
                                    elongation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">CLB2</td>
                                <td align="left" colspan="1" rowspan="1">CCNB1</td>
                                <td align="left" colspan="1" rowspan="1">B-type cyclin involved in cell cycle
                                    progression</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">FYV7</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Essential protein required for maturation of 18S
                                    rRNA</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">GIS2</td>
                                <td align="left" colspan="1" rowspan="1">ZCCHC13</td>
                                <td align="left" colspan="1" rowspan="1">Protein proposed to be involved in the RAS/cAMP
                                    signaling pathway</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">HIT1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein of unknown function, required for growth at
                                    high temperature</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">HMO1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Chromatin associated high mobility group (HMG)
                                    family member involved in genome maintenance</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">IPK1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Inositol 1,3,4,5,6-pentakisphosphate 2-kinase</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">LSM7</td>
                                <td align="left" colspan="1" rowspan="1">LSM7</td>
                                <td align="left" colspan="1" rowspan="1">Lsm (Like Sm) protein, part of heteroheptameric
                                    complexes mRNA decayor in processing tRNA, snoRNA, and rRNA,
                                    involved in stress granule formation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">LTV1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Component of the GSE complex, which is required for
                                    proper sorting of amino acid permease Gap1p</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">MFT1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Subunit of the THO complex, which is a nuclear
                                    complex involved in transcription elongation and mitotic
                                    recombination</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">MRT4</td>
                                <td align="left" colspan="1" rowspan="1">MRTO4</td>
                                <td align="left" colspan="1" rowspan="1">Protein involved in mRNA turnover and ribosome
                                    assembly, localizes to the nucleolus</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">NOP16</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Constituent of 66S pre-ribosomal particles,
                                    involved in 60S ribosomal subunit biogenesis</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">NPR2</td>
                                <td align="left" colspan="1" rowspan="1">TUSC4</td>
                                <td align="left" colspan="1" rowspan="1">Component of an evolutionarily conserved Npr2/3
                                    complex that mediates downregulation of TORC1 activity in
                                    response to amino acid limitation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">NSR1</td>
                                <td align="left" colspan="1" rowspan="1">NCL</td>
                                <td align="left" colspan="1" rowspan="1">Nucleolar protein that binds nuclear localization
                                    sequences, required for pre-rRNA processing and ribosome
                                    biogenesis</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">NUP84</td>
                                <td align="left" colspan="1" rowspan="1">NUP107</td>
                                <td align="left" colspan="1" rowspan="1">Subunit of the nuclear pore complex (NPC), plays a
                                    role in nuclear mRNA export and NPC biogenesis</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">PPM1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Carboxyl methyltransferase, methylates the C
                                    terminus of the protein phosphatase 2A catalytic subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">PUB1</td>
                                <td align="left" colspan="1" rowspan="1">TIAL1</td>
                                <td align="left" colspan="1" rowspan="1">Poly (A)+ RNA-binding protein, component of
                                    glucose deprivation induced stress granules, involved in
                                    P-body-dependent granule assembly</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">RAD50</td>
                                <td align="left" colspan="1" rowspan="1">RAD50</td>
                                <td align="left" colspan="1" rowspan="1">Subunit of MRX complex, involved in processing
                                    double-strand DNA breaks in vegetative cells</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">RPL14A</td>
                                <td align="left" colspan="1" rowspan="1">RPL14</td>
                                <td align="left" colspan="1" rowspan="1">Component of the large (60S) ribosomal subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">RPL19B</td>
                                <td align="left" colspan="1" rowspan="1">RPL19</td>
                                <td align="left" colspan="1" rowspan="1">Component of the large (60S) ribosomal subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">RPP2B</td>
                                <td align="left" colspan="1" rowspan="1">RPLP2</td>
                                <td align="left" colspan="1" rowspan="1">Ribosomal protein P2 beta, a component of the
                                    ribosomal stalk</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">RPS10A</td>
                                <td align="left" colspan="1" rowspan="1">RPS10L</td>
                                <td align="left" colspan="1" rowspan="1">Component of the small (40S) ribosomal subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">RPS6B</td>
                                <td align="left" colspan="1" rowspan="1">RPS6</td>
                                <td align="left" colspan="1" rowspan="1">Component of the small (40S) ribosomal subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">RPS8A</td>
                                <td align="left" colspan="1" rowspan="1">RPS8</td>
                                <td align="left" colspan="1" rowspan="1">Component of the small (40S) ribosomal subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">SSE1</td>
                                <td align="left" colspan="1" rowspan="1">HSPA4</td>
                                <td align="left" colspan="1" rowspan="1">Hsp70 ATPase that is a component of the heat shock
                                    protein Hsp90 chaperone complex, nucleotide exchange factor for
                                    Ssa1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">THP2</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Subunit of the THO complex and TREX complex,
                                    involved in telomere maintenance</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">TSR2</td>
                                <td align="left" colspan="1" rowspan="1">TSR2</td>
                                <td align="left" colspan="1" rowspan="1">Protein with a potential role in pre-rRNA
                                    processing</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">VPS64</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein required for cytoplasm to vacuole targeting
                                    of proteins</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YDR417C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame, partially overlaps the
                                    verified ORF RPL12B/YDR418W</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YGL072C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame, partially overlaps the
                                    verified gene HSF1</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YGL088W</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame, partially overlaps
                                    snR10, a snoRNA required for preRNA processing</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YGL165C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame, partially overlaps the
                                    verified ORF CUP2/YGL166W</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YNR005C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppressor</td>
                                <td align="left" colspan="1" rowspan="1">YOR309C</td>
                                <td align="left" colspan="1" rowspan="1">AL138690.1</td>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame, partially overlaps the
                                    verified gene NOP58</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">ATP5</td>
                                <td align="left" colspan="1" rowspan="1">ATP50</td>
                                <td align="left" colspan="1" rowspan="1">Subunit 5 of the stator stalk of mitochondrial F1F0
                                    ATP synthase</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">CBT1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein involved in 5′ end processing of
                                    mitochondrial COB, 15S_rRNA, and RPM1 transcripts</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">COX5A</td>
                                <td align="left" colspan="1" rowspan="1">COX5A</td>
                                <td align="left" colspan="1" rowspan="1">Subunit Va of cytochrome c oxidase</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">EAF1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Component of the NuA4 histone acetyltransferase
                                    complex</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">FUM1</td>
                                <td align="left" colspan="1" rowspan="1">FH</td>
                                <td align="left" colspan="1" rowspan="1">Fumarase, converts fumaric acid to L-malic acid in
                                    the TCA cycle</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">GCN4</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Basic leucine zipper transcriptional activator of
                                    amino acid biosynthetic genes in response to amino acid
                                    starvation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">KGD2</td>
                                <td align="left" colspan="1" rowspan="1">DLST</td>
                                <td align="left" colspan="1" rowspan="1">Dihydrolipoyl transsuccinylase, component of the
                                    mitochondrial alpha-ketoglutarate dehydrogenase complex</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">MAK32</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein necessary for structural stability of L-A
                                    double-stranded RNA-containing particles</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">MRP13</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Mitochondrial ribosomal protein of the small
                                    subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">MRP49</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Mitochondrial ribosomal protein of the large
                                    subunit, not essential for mitochondrial translation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">MRPL39</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Mitochondrial ribosomal protein of the large
                                    subunit</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">MSS1</td>
                                <td align="left" colspan="1" rowspan="1">GTPBP3</td>
                                <td align="left" colspan="1" rowspan="1">Mitochondrial protein, involved in the
                                    5-carboxymethylaminomethyl modification of the wobble uridine
                                    base in mitochondrial tRNAs</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">OCA1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Putative protein tyrosine phosphatase, required for
                                    cell cycle arrest in response to oxidative damage of DNA</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">REC102</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein involved in early stages of meiotic
                                    recombination</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">RIM15</td>
                                <td align="left" colspan="1" rowspan="1">MAST1</td>
                                <td align="left" colspan="1" rowspan="1">Glucose-repressible protein kinase involved in
                                    signal transduction during cell proliferation in response to
                                    nutrients</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">RTT103</td>
                                <td align="left" colspan="1" rowspan="1">RPRD1A</td>
                                <td align="left" colspan="1" rowspan="1">Protein that interacts with exonuclease Rat1p and
                                    Rai1p and plays a role in transcription termination by RNA
                                    polymerase II</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">SLM3</td>
                                <td align="left" colspan="1" rowspan="1">TRMU</td>
                                <td align="left" colspan="1" rowspan="1">tRNA-specific 2-thiouridylase, responsible for
                                    2-thiolation of the wobble base of mitochondrial tRNAs</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">SLT2</td>
                                <td align="left" colspan="1" rowspan="1">UHMK1</td>
                                <td align="left" colspan="1" rowspan="1">Serine/threonine MAP kinase involved in regulating
                                    the maintenance of cell wall integrity and progression through
                                    the cell cycle</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">TBS1</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Putative protein of unknown function</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">YDL032W</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Dubious open reading frame unlikely to encode a
                                    protein, partially overlaps verified gene SLM3/YDL033C</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">YDR049W</td>
                                <td align="left" colspan="1" rowspan="1">ANKZF1</td>
                                <td align="left" colspan="1" rowspan="1">Zinc finger protein, putative transcription factor
                                    that may interact with proteins involved in histone acetylation
                                    or deacetylation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">YDR248C</td>
                                <td align="left" colspan="1" rowspan="1">C9orf103</td>
                                <td align="left" colspan="1" rowspan="1">Putative protein of unknown function</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">YER128W</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Putative protein of unknown function</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Enhancer</td>
                                <td align="left" colspan="1" rowspan="1">YLR218C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">Protein that localizes to the mitochondrial
                                    intermembrane space</td>
                            </tr>
                        </tbody>
                    </table></alternatives></table-wrap>
            </sec>
        </sec>
        <sec id="s3">
            <title>Discussion</title>
            <p>We have established a pure protein aggregation assay and a yeast model to gain
                insight into how FUS contributes to disease pathogenesis. We have recently used a
                similar approach to define mechanisms underpinning TDP-43 aggregation and toxicity
                    <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>, as well
                as the pathogenic mechanism of ALS-linked TDP-43 mutants <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>. Using the yeast system we
                have also identified potent modifiers of TDP-43 toxicity <xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>. One such modifier is ataxin 2,
                which can harbor intermediate-length polyQ expansions that are associated with
                increased risk for ALS in humans <xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>. Like TDP-43, we find that, in isolation, FUS is an
                intrinsically aggregation-prone protein. FUS rapidly assembles into pore-like
                oligomeric species and filamentous structures that closely resemble the
                ultrastructure of FUS aggregates in degenerating motor neurons of ALS patients.
                Thus, all the information needed to assemble these structures is encoded in the
                primary sequence of FUS. Like TDP-43, expression of FUS in yeast results in
                cytoplasmic FUS aggregation, colocalization of these inclusions with stress granules
                and toxicity, modeling key features seen in human disease <xref ref-type="bibr" rid="pbio.1000614-Kwiatkowski1">[17]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Vance1">[18]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Huang1">[21]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Urwin1">[23]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. In further similarity to
                TDP-43, disabling the RNA binding activity of FUS reduced toxicity. Thus, we propose
                that the misfolded forms of FUS likely cause toxicity by binding to and sequestering
                essential RNAs or perhaps by interfering with the normal shuttling, stability, or
                metabolism of RNA. Importantly, FUS immunoreactive cytoplasmic inclusions now appear
                to characterize ALS and FTLD broadly, not only rare cases linked to FUS mutations
                    <xref ref-type="bibr" rid="pbio.1000614-Huang1">[21]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Urwin1">[23]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Deng1">[92]</xref>. Together these
                advances make it clear that FUS is a key aggregated protein in ALS, just as
                α-synuclein is in Parkinson's disease and huntingtin is in
                Huntington's disease <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>.</p>
            <p>Despite these similarities, we have uncovered key differences in the regions of the
                proteins that dictate aggregation and toxicity. For TDP-43, pure protein data and
                results from yeast and other model systems suggest that the C-terminal prion-like
                domain (<xref ref-type="fig" rid="pbio-1000614-g001">Figure 1A</xref>) <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref> plays a major
                role in driving aggregation <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Ayala1">[66]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Ash1">[93]</xref>. For FUS, we find that the N-terminal region, containing
                a predicted prion-like domain (<xref ref-type="fig" rid="pbio-1000614-g001">Figure
                    1A</xref>) <xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref>, is also important for aggregation in vitro and for
                aggregation and toxicity in yeast cells. However, C-terminal regions in FUS,
                particularly the first RGG domain, are also critical. Intriguingly, the first RGG
                domain also contains a short region (amino acids 391–407) that is detected by
                an algorithm designed to isolate prion-like domains <xref ref-type="bibr" rid="pbio.1000614-Alberti1">[32]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Cushman1">[33]</xref> but does not quite reach
                significance (<xref ref-type="supplementary-material" rid="pbio.1000614.s001">Figure
                    S1</xref>). The requirement for two specific, disparate portions of FUS for the
                ordered formation of filamentous structures raises the possibility that
                communication between the N-terminal prion-like domain (amino acids 1–239) and
                first RGG domain (amino acids 374–422) might mediate a self-organizing
                assembly process. This process might even involve an intermolecular domain swap: a
                common mechanism that usually involves domains at the N- and C-terminal ends of
                proteins and can promote the polymerization of filamentous structures in various
                designed and natural proteins <xref ref-type="bibr" rid="pbio.1000614-Liu1">[94]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Ogihara1">[96]</xref>. Thus, strategies aimed at targeting either the
                appropriate N- or C-terminal portions of FUS could be effective at mitigating FUS
                aggregation in disease. Indeed, our in vitro and yeast models could open up new
                therapeutic avenues and provide the basic screening system to isolate specific
                molecules able to antagonize and reverse FUS aggregation and toxicity.</p>
            <p>With regard to toxicity, the minimal toxic FUS fragment comprises the N-terminal
                prion-like domain, RRM, and the first RGG domain (1–422). These findings
                contrast with TDP-43, where the prion-like domain plus RRM2 are sufficient to drive
                aggregation and toxicity <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>. Indeed, a proteolytic fragment corresponding to these
                portions of TDP-43 is a pathogenic signature of ALS and FTLD-TDP <xref ref-type="bibr" rid="pbio.1000614-Neumann1">[3]</xref>. By contrast, a
                similar pathogenic FUS fragment has not been identified in ALS or FTLD-FUS patients,
                which likely reflects the fact that the equivalent regions of FUS (1–373) are
                insufficient for aggregation and toxicity.</p>
            <p>Mutations in the C-terminal domains of FUS and TDP-43 have both been linked to ALS
                    <xref ref-type="bibr" rid="pbio.1000614-Pesiridis1">[6]</xref>,<xref ref-type="bibr" rid="pbio.1000614-LagierTourenne1">[37]</xref>.
                Interestingly, whereas some ALS-linked mutations in TDP-43 can increase stability,
                aggregation, cytoplasmic accumulation, and toxicity in yeast, mammalian cells, and
                animal models <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Ritson1">[78]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Barmada1">[80]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Ling1">[97]</xref>, the mechanisms by which FUS mutations contribute to
                disease appear to be distinct. Our results in yeast and with pure protein show that
                C-terminal FUS mutations do not promote aggregation per se. Instead of enhancing
                aggregation, these mutations, especially those in the extreme C-terminal region of
                the protein (amino acids 502–526), disrupt a NLS, leading to increased
                cytoplasmic accumulation of FUS <xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. Interestingly, the severity of the effects of the
                mutations on FUS localization in cells correlate well with age of onset of ALS in
                humans, with stronger mutations resulting in earlier disease onset and more
                cytoplasmic FUS accumulation <xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. These results suggest distinct mechanisms by which
                ALS-linked FUS and TDP-43 mutations contribute to disease.</p>
            <p>Despite these differences, both TDP-43 and FUS have been shown to re-localize to
                stress granules and P-bodies, transient sites of RNA processing that assemble during
                cellular stress or injury and are conserved from yeast to man <xref ref-type="bibr" rid="pbio.1000614-Colombrita1">[59]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Nonhoff1">[60]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Freibaum1">[62]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Balagopal1">[98]</xref>. Both TDP-43 and FUS have
                been purified in a complex with one another and with various components of the RNA
                processing machinery, including stress granules and P-bodies <xref ref-type="bibr" rid="pbio.1000614-Freibaum1">[62]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Ling1">[97]</xref>. Moreover, stress granule
                markers, including PABP-1, are present in disease-associated cytoplasmic FUS
                accumulations <xref ref-type="bibr" rid="pbio.1000614-Dormann1">[52]</xref>. ALS-linked FUS mutants appear more prone to entering
                stress granules <xref ref-type="bibr" rid="pbio.1000614-Bosco1">[51]</xref>. However, it remains unclear whether stress granule
                assembly contributes to FUS toxicity or is simply a downstream consequence of
                cellular stress associated with degeneration. Our identification of several key
                P-body and stress granule components as potent genetic modifiers of FUS toxicity
                suggests a mechanistic connection that, if validated in animal models, represents a
                potentially tractable new therapeutic angle. We also note that for the majority of
                overexpression or deletion suppressors that we have examined so far, we do not see a
                major difference in FUS aggregation. This suggests that these genes act downstream
                or in parallel to FUS aggregation. Alternatively, these modifiers may affect FUS
                aggregation (e.g., composition or dynamics of FUS inclusions) in subtle ways that we
                have so far not been able to visualize.</p>
            <p>Curiously, there was a conspicuous lack of overlap between genetic modifiers of FUS
                toxicity and TDP-43 toxicity. These genetic data suggest two interesting
                possibilities. On one hand, targeting the modifiers in common between TDP-43 and FUS
                might have broad therapeutic utility for ALS. On the other hand, defining the key
                differences between FUS and TDP-43 pathogenic mechanisms will empower a more
                accurate understanding of how these seemingly similar proteins might contribute to
                disease in different ways.</p>
            <p>What is the connection between TDP-43, FUS, and ALS? Does each protein contribute
                separately to the disease, or do they share a common disease pathway? The lack of
                overlap in genetic modifiers suggests that the precise mechanism of TDP-43 and FUS
                toxicity may be subtly different. Moreover, initial reports suggested FUS
                cytoplasmic accumulations were specific to rare cases of ALS, owing to FUS
                mutations, and that these inclusions were devoid of TDP-43 aggregates <xref ref-type="bibr" rid="pbio.1000614-Kwiatkowski1">[17]</xref>. However,
                in one study, using optimized antigen-unmasking methods, FUS cytoplasmic
                immunoreactivity has recently been detected broadly in sporadic and familial ALS,
                including cases with TDP-43 aggregates, as well as cases without FUS mutations <xref ref-type="bibr" rid="pbio.1000614-Deng1">[92]</xref>. Further, FUS and
                TDP-43 have been found to physically associate in a complex <xref ref-type="bibr" rid="pbio.1000614-Ling1">[97]</xref>, indicating that both TDP-43 and
                FUS, even in the WT state, likely contribute broadly to ALS pathogenesis. Therefore,
                defining mechanisms by which WT versions of these proteins are toxic to cells, as we
                report here for FUS and in previous studies for TDP-43 <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>–<xref ref-type="bibr" rid="pbio.1000614-Elden1">[16]</xref>, will likely be informative to
                not only rare familial cases but to the much more common sporadic forms as well.</p>
            <p>The discovery of RNA-binding proteins TDP-43 and FUS in ALS has re-invigorated the
                focus on RNA processing pathways in ALS <xref ref-type="bibr" rid="pbio.1000614-ChenPlotkin1">[5]</xref>,<xref ref-type="bibr" rid="pbio.1000614-LagierTourenne1">[37]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Lin1">[99]</xref>. Our identification of potent
                genetic modifiers of FUS toxicity in yeast, including a large number of conserved
                RNA metabolism genes, as well as key stress granule components, will provide a
                toehold for future studies aimed at elucidating the mechanisms by which FUS
                interfaces with these RNA processing pathways in disease. However, our study also
                suggests caution in assuming, based on sequence and structural similarity, that both
                TDP-43 and FUS contribute to disease via the same or similar mechanisms <xref ref-type="bibr" rid="pbio.1000614-LagierTourenne2">[38]</xref>. While
                there are clear similarities between the two proteins, there are also important
                differences, which we have defined here. Furthermore, the fact that genetic
                modifiers uncovered in screens for TDP-43 and FUS proteotoxicty are surprisingly
                distinct argues further that there are likely different underlying pathogenic
                mechanisms for FUS and TDP-43 proteinopathies. This conceptual framework we have
                established will aid the development of novel therapeutic approaches.</p>
        </sec>
        <sec id="s4" sec-type="materials|methods">
            <title>Materials and Methods</title>
            <sec id="s4a">
                <title>Yeast Strains, Media, and Plasmids</title>
                <p>Yeast cells were grown in rich media (YPD) or in synthetic media lacking uracil
                    and containing 2% glucose (SD/-Ura), raffinose (SRaf/-Ura), or galactose
                    (SGal/-Ura).</p>
                <p>A FUS Gateway entry clone was obtained from Invitrogen, containing full-length
                    human FUS in the vector pDONR221. A Gateway LR reaction was used to shuttle FUS
                    into Gateway-compatible yeast expression vectors (pAG vectors, <xref ref-type="bibr" rid="pbio.1000614-Alberti2">[100]</xref>,
                        <ext-link ext-link-type="uri" xlink:href="http://www.addgene.org/yeast_gateway" xlink:type="simple">http://www.addgene.org/yeast_gateway</ext-link>). To generate C-terminally
                    YFP-tagged FUS constructs, a two-step PCR protocol was used to amplify FUS (or
                    truncated versions) without a stop codon and incorporate the Gateway attB1 and
                    attB2 sites along with a Kozak consensus sequence. Resulting PCR products were
                    shuttled into pDONR221 using a Gateway BR reaction. The entry clones
                        (FUS<sub>nostop</sub>) were then used in LR reactions with
                    pAG426Gal-ccdB-YFP to generate the 2 micron FUS-YFP fusion constructs and
                    pAG416Gal-ccdB-YFP to generate the CEN FUS-YFP constructs. Primer sequences are
                    available upon request. To generate the integrating FUS construct, the FUS entry
                    clone was used in an LR reaction with pAG303Gal-ccdB. Expression constructs for
                    TDP-43 have been described previously <xref ref-type="bibr" rid="pbio.1000614-Johnson1">[14]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>.</p>
                <p>ALS-linked point mutations, based on <xref ref-type="bibr" rid="pbio.1000614-LagierTourenne2">[38]</xref>, were introduced
                    into FUS using the QuickChange Site-Directed Mutagenesis Kit (Agilent) according
                    to the manufacturer's instructions. Mutations were verified by DNA
                    sequencing. To disable FUS RNA binding, we mutated four conserved phenylalanine
                    residues (aa 305, 341, 359, 368) within the FUS RNA recognition motif (RRM) to
                    leucine.</p>
                <p>Two micron plasmid constructs (e.g., pAG426Gal-FUS-YFP) were transformed into
                    BY4741 (<italic>MATa his3 leu2 met15 ura3</italic>). The FUS integrating strain
                    was generated by linearizing pAG303Gal-FUS by Nhe I restriction digest, followed
                    by transformation into the w303 strain (<italic>MATa can1-100, his3-11,15,
                        leu2-3,112, trp1-1, ura3-1, ade2-1</italic>).</p>
                <p>To introduce the SV40 NLS to the N-terminus of FUS, we used PCR, incorporating
                    DNA sequences encoding the SV40 NLS (PPKKKRKV), optimized for yeast translation
                        (<named-content content-type="gene" xlink:type="simple">CCA CCA AAA AAA AAA AGA AAA
                        GTT</named-content>) into the forward primer, following a start codon (ATG)
                    and in frame with FUS. We verified the construct by DNA sequencing.</p>
            </sec>
            <sec id="s4b">
                <title>Yeast Transformation and Spotting Assays</title>
                <p>Yeast procedures were performed according to standard protocols <xref ref-type="bibr" rid="pbio.1000614-Guthrie1">[101]</xref>. We used
                    the PEG/lithium acetate method to transform yeast with plasmid DNA <xref ref-type="bibr" rid="pbio.1000614-Ito2">[102]</xref>. For spotting
                    assays, yeast cells were grown overnight at 30°C in liquid media containing
                    raffinose (SRaf/-Ura) until they reached log or mid-log phase. Cultures were
                    then normalized for OD600, serially diluted and spotted onto synthetic solid
                    media containing glucose or galactose lacking uracil and were grown at 30°C
                    for 2–3 d.</p>
            </sec>
            <sec id="s4c">
                <title>Immunoblotting</title>
                <p>Yeast lysates were subjected to SDS/PAGE (4%–12% gradient,
                    Invitrogen) and transferred to a PVDF membrane (Invitrogen). Membranes were
                    blocked with 5% nonfat dry milk in PBS for 1 h at room temperature.
                    Primary antibody incubations were performed overnight at 4°C or at room
                    temperature for 1–2 h. After washing with PBS, membranes were incubated
                    with a horseradish peroxidase-conjugated secondary antibody for 1 h at room
                    temperature, followed by washing in PBS+0.1% Tween 20 (PBST).
                    Proteins were detected with Immobilon Western HRP Chemiluminescent Substrate
                    (Millipore). Primary antibody dilutions were as follows: anti-GFP monoclonal
                    antibody (Roche), 1∶5,000; Phosphoglycerate Kinase 1 (PGK1) antibody
                    (Invitrogen), 1∶500; glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
                    1∶5,000; FUS rabbit polyclonal antibody (Bethyl), 1∶10,000.
                    HRP-conjugated anti-mouse and anti-rabbit secondary antibodies were used at
                    1∶5,000.</p>
            </sec>
            <sec id="s4d">
                <title>Fluorescence Microscopy</title>
                <p>For fluorescence microscopy experiments, single colony isolates of the yeast
                    strains were grown to mid-log phase in SRaf/-Ura media at 30°C. Cultures
                    were spun down and resuspended in the same volume of SGal/-Ura to induce
                    expression of the FUS constructs. Cultures were induced with galactose for
                    4–6 h before being stained with DAPI to visualize nuclei and processed for
                    microscopy. Images were obtained using an Olympus IX70 inverted microscope and a
                    Photometrics CoolSnap HQ 12-bit CCD camera. Z-stacks of several fields were
                    collected for each strain. The images were deblurred using a nearest neighbor
                    algorithm in the Deltavision Softworx software and representative cells were
                    chosen for figures.</p>
            </sec>
            <sec id="s4e">
                <title>Quantification of FUS Aggregation in Yeast</title>
                <p>To assess differences in aggregation between wild-type and mutant FUS, yeast
                    cultures were grown, induced, and processed as described above after having
                    normalized all yeast cultures to OD<sub>600nm</sub> = 0.2
                    prior to galactose induction. After 6 h of induction, the identities of the
                    samples were blinded to the observer before being examined. Several fields of
                    cells were randomly chosen using the DAPI filter to prevent any bias towards
                    populations of cells with increased amounts of aggregation in addition to
                    obtaining the total number of cells in any given field. At least 200 cells per
                    sample were counted for each replicate. Only cells with greater than three foci
                    under the YFP channel were considered as cells with aggregating FUS.</p>
            </sec>
            <sec id="s4f">
                <title>Yeast Plasmid Overexpression Screen</title>
                <p>Plasmids of 5,500 full-length yeast ORFs (Yeast FLEXGene collection, <xref ref-type="bibr" rid="pbio.1000614-Hu1">[82]</xref>) were dried in
                    individual wells of 96-well microtiter plates and transformed into a strain
                    expressing FUS integrated at the <italic>HIS3</italic> locus. A standard lithium
                    acetate transformation protocol was modified for automation and used by
                    employing a BIOROBOT Rapidplate 96-well pipettor (Qiagen). The transformants
                    were grown in synthetic deficient media lacking uracil (SD-Ura) with glucose. 48
                    h later, the cultures were inoculated into fresh SRaf-Ura media and allowed to
                    reach stationary phase. Then the cells were spotted on to SD-Ura + glucose
                    and SD-Ura + galactose agar plates. Suppressors and enhancers of FUS were
                    identified on galactose plates after 2–3 d of growth at 30°C. The
                    entire screen was repeated three times and only hits that reproduced all three
                    times were selected for further validation. Toxicity enhancers were further
                    tested in WT yeast cells to eliminate genes that were simply toxic when
                    overexpressed. Immunoblotting was performed to test all modifiers for their
                    effect on FUS expression.</p>
            </sec>
            <sec id="s4g">
                <title>Yeast Deletion Screen</title>
                <p>This screen was performed as described in <xref ref-type="bibr" rid="pbio.1000614-Tong1">[86]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Tong2">[87]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Tong3">[103]</xref>, with some modifications,
                    using a Singer RoToR HDA (Singer Instruments, Somerset, UK). The
                    galactose-inducible FUS expression construct (pAG416Gal-FUS-YFP) was introduced
                    into <italic>MAT</italic>α strain Y7092 (gift from C. Boone) to generate the
                    query strain. This query strain was mated to the yeast haploid deletion
                    collection of non-essential genes (<italic>MAT</italic>a, each gene deleted with
                    KanMX cassette (confers resistance to G418)). Haploid mutants harboring the FUS
                    expression plasmid were grown in the presence of glucose (FUS expression
                    “off”) or galactose (FUS expression “on”). Following
                    growth at 30°C for 2 d, plates were photographed and colony sizes measured
                    by ImageJ image analysis software, based on <xref ref-type="bibr" rid="pbio.1000614-Collins1">[104]</xref>. The entire screen was
                    repeated three times and only hits that reproduced all three times were selected
                    for further validation by random spore analysis on DNA sequencing of deletion
                    strain bar codes. Deletion strains that grew poorly on galactose were eliminated
                    based on published data on deletion strain fitness on galactose as well as in
                    house measurements using the yeast deletion collection.</p>
            </sec>
            <sec id="s4h">
                <title>FUS Purification</title>
                <p>FUS and FUS deletion mutants were expressed and purified from <italic>Escherichia
                        coli</italic> as GST-tagged proteins. FUS constructs were generated in GV13
                    to yield a TEV protease cleavable GST-FUS protein, GST-TEV-FUS, and
                    overexpressed in <italic>E. coli</italic> BL21 DE3 cells (Agilent). Protein was
                    purified over a glutathione-sepharose column (GE) according to the
                    manufacturer's instructions. Proteins were eluted from the glutathione
                    sepharose with 50 mM Tris-HCl pH 8, 200 mM trehalose, and 20 mM glutathione.
                    After purification, proteins were concentrated to 10 µM or greater using
                    Amicon Ultra-4 centrifugal filter units (10 kDa molecular weight cut-off;
                    Millipore). Protein was then centrifuged for 30 min at 16,100 g to remove any
                    aggregated material. After centrifugation, the protein concentration was
                    determined by Bradford assay (Bio-Rad) and the proteins were used immediately
                    for aggregation reactions. GST-TEV-TDP-43 was purified as described <xref ref-type="bibr" rid="pbio.1000614-Johnson2">[15]</xref>.</p>
            </sec>
            <sec id="s4i">
                <title>FUS-RNA binding Assay</title>
                <p>RNA-binding assays were performed as described <xref ref-type="bibr" rid="pbio.1000614-Rothrock1">[105]</xref>. Briefly, FUS RNA probe
                    was transcribed by T7 polymerase from DNA template (<named-content content-type="gene" xlink:type="simple">5′-GTAATACGACTCACTATAGGGGAAAATTAATGTGTGTGTGTGGAAAATT-3′</named-content>)
                    with <sup>32</sup>P-labeled UTP. Probes were gel-purified and adjusted to
                        10<sup>4</sup> c.p.m./µl specific activity. Standard binding reactions
                    were carried out in 10 µl, with a final concentration of 4 mM
                        MgCl<sub>2</sub>, 25 mM phosphocreatine, 1.25 mM ATP, 1.3% polyvinyl
                    alcohol, 25 ng of yeast tRNA, 0.8 mg of BSA, 1 mM DTT, 0.1 µl Rnasin
                    (Promega, 40 U/ml), 75 mM KCl, 10 mM Tris, pH 7.5, 0.1 mM EDTA, 10%
                    glycerol, and 0.15 µM to 5 µM GST-FUS or GST. Binding reactions were
                    incubated for 20 min at 30°C with <sup>32</sup>P-labeled probe. After
                    binding, heparin was added to a final concentration of 0.5 µg/ml;
                    reactions were analyzed on a 4.5% native gel (Acrylamide/Bis 29:1,
                    BioRad).</p>
            </sec>
            <sec id="s4j">
                <title>FUS In Vitro Aggregation Assay</title>
                <p>Aggregation was initiated by the addition of TEV protease (Invitrogen) to
                    GST-TEV-FUS (2.5–5 µM) in assembly buffer (AB): 100 mM TrisHCl pH 8,
                    200 mM trehalose, 0.5 mM EDTA, and 20 mM glutathione. Aggregation reactions were
                    incubated at 22°C for 0–90 min with or without agitation at 700 rpm in
                    an Eppendorf Thermomixer. No aggregation occurred unless TEV protease was added
                    to separate GST from FUS or TDP-43. Turbidity was used to assess aggregation by
                    measuring absorbance at 395 nm. For sedimentation analysis, reactions were
                    centrifuged at 16,100 g for 10 min at 25°C. Supernatant and pellet fractions
                    were then resolved by SDS-PAGE and stained with Coomassie Brilliant Blue, and
                    the amount in either fraction determined by densitometry in comparison to known
                    quantities of FUS. For electron microscopy (EM) of in vitro aggregation
                    reactions, protein samples (20 µl of a 2.5 µM solution) were
                    adsorbed onto glow-discharged 300-mesh Formvar/carboncoated copper grid
                    (Electron Microscopy Sciences) and stained with 2% (w/v) aqueous uranyl
                    acetate. Excess liquid was removed, and grids were allowed to air dry. Samples
                    were viewed using a JEOL 1010 transmission electron microscope.</p>
            </sec>
            <sec id="s4k">
                <title>Visualizing P-Bodies and Stress Granules in Yeast</title>
                <p>We used fluorescent markers of P-bodies and stress granules and live cell imaging
                    to monitor stress granule and P-body formation in yeast, based on standard
                    protocols <xref ref-type="bibr" rid="pbio.1000614-Buchan2">[63]</xref>. First, we transformed yeast strain BY4741 with
                    pAG423GAL-FUS-YFP. This strain was then transformed with plasmids encoding
                    P-body markers (Lsm1-mCherry, LEU2 or Dcp2-RFP, LEU2) or stress granule markers
                    (Pub1-RFP, URA3 or CFP-Pbp1, URA3) separately. Transformants were grown
                    overnight to mid-log phase in raffinose-containing media. To induce expression
                    of FUS-YFP, galactose was added to 2% and cells were incubated at
                    30°C for 4 h and then processed for microscopy. We used a spinning disk
                    confocal microscope to monitor the YFP, CFP, and RFP signals in live cells. For
                    each channel, 60 z-sections were acquired at 0.1 µm increments at
                    23°C. Figures display the maximum projection of each channel.</p>
            </sec>
            <sec id="s4l">
                <title>FUS and Modifier Genes Transfection in Mammalian Cells</title>
                <p>HEK293T cells were plated in 96-well format and transfected with FuGene (Roche)
                    according to the manufacturer's instructions. 72 h post-transfection, MTT
                    (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) was added
                    to each well and incubated for 3 h at 37°C. Acidic Isoproponal (40 mM HCl)
                    was then added to each well to solubilize the blue formazan crystals. Absorbance
                    of each well was read with a Tecan Safire II plate reader using 570 nm for
                    absorbance and 630 nm as a reference wavelength. Absorbance measurements were
                    normalized to the absorbance of untransfected cells and used to calculate a
                    percent viability for each condition.</p>
            </sec>
        </sec>
        <sec id="s5">
            <title>Supporting Information</title>
            <supplementary-material id="pbio.1000614.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.s001" xlink:type="simple">
                <label>Figure S1</label>
                <caption>
                    <p>Prion domain prediction algorithm identifies prion-like domains in TDP-43
                        (top) and FUS/TLS (bottom). Note that the prion-like domain (PrD) of TDP-43
                        is located in the C-terminal region, whereas the PrD of FUS/TLS is in the
                        N-terminal region. There is an additional peak of PrD character predicted by
                        the algorithm in FUS/TLS aa 391–407. For additional details on design
                        and implementation of this prion domain prediction algorithm, see <xref ref-type="bibr" rid="pbio.1000614-Doi1">[33]</xref>,<xref ref-type="bibr" rid="pbio.1000614-Woulfe1">[34]</xref>.</p>
                    <p>(3.34 MB TIF)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pbio.1000614.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.s002" xlink:type="simple">
                <label>Figure S2</label>
                <caption>
                    <p>FUS and TDP-43 co-localize in yeast cells. FUS-YFP and TDP-43-CFP were
                        co-transformed into yeast cells and their localization visualized by
                        fluorescence microscopy. FUS-YFP and TDP-43-CFP co-localized to the same
                        subcellular foci (arrows).</p>
                    <p>(1.46 MB TIF)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pbio.1000614.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.s003" xlink:type="simple">
                <label>Figure S3</label>
                <caption>
                    <p>FUS localizes to the nucleus and cytoplasm when expressed at lower levels.
                        Yeast strain YEF6030 (YEF473a NUP57-mCherry-His3), harboring a nuclear
                        envelope marker, to visualize the nucleus in live cells, was transformed
                        with 416GPD-FUS-YFP. FUS localization in live cells was visualized using a
                        spinning disc confocal microscope. At this level of expression, FUS-YFP
                        localized to the nucleus (arrows) and cytoplasm in a diffuse pattern.</p>
                    <p>(1.98 MB TIF)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pbio.1000614.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.s004" xlink:type="simple">
                <label>Figure S4</label>
                <caption>
                    <p>FUS truncation proteins localize to the nucleus. DAPI stained cells confirm
                        nuclear localization of FUS truncation constructs 1–168aa,
                        1–269aa, and 1–373aa (also see <xref ref-type="fig" rid="pbio-1000614-g003">Figure 3</xref> of main text).</p>
                    <p>(4.59 MB TIF)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pbio.1000614.s005" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1000614.s005" xlink:type="simple">
                <label>Figure S5</label>
                <caption>
                    <p>Verifying FUS toxicity modifiers from plasmid overexpression screen. Spotting
                        assay showing serial dilutions of yeast cells expressing FUS along with
                        empty vector control, four enhancers, or six suppressors from the
                        screen.</p>
                    <p>(4.44 MB TIF)</p>
                </caption>
            </supplementary-material>
        </sec>
    </body>
    <back>
        <ack>
            <p>We thank Dan Ramos, Pier Hart, and Renske Erion for assistance with the yeast genetic
                screens and Sarah Glenn and Kristen Lynch for assistance with the RNA-binding
                studies. We thank Jasmine Zhao of the PENN CDB Microscopy Core for expert assistance
                with microscopy. We thank Alex Chavez for providing the CYC1 and NOP1 yeast promoter
                plasmids and Jasmine Smith for advice on the SV40 NLS experiments. We thank Roy
                Parker for providing some of the yeast stress granule and P-body markers and
                Cornelia Kurischko for advice on visualizing stress granules and P-bodies in yeast.
                We thank Julien Couthouis and Rose Li for help with some of the FUS and TDP-43
                plasmid constructs. We thank Mark Lemmon and Morgan DeSantis for comments on the
                manuscript and helpful suggestions. We also thank the Petsko and Lindquist
                laboratories for communicating their results with us prior to publication.</p>
        </ack>
        <ref-list>
            <title>References</title>
            <ref id="pbio.1000614-Rosen1">
                <label>1</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Rosen</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Siddique</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Patterson</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Figlewicz</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sapp</surname>
                            <given-names>P</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1993</year>
                    <article-title>Mutations in Cu/Zn superoxide dismutase gene are associated with
                        familial amyotrophic lateral sclerosis.</article-title>
                    <source>Nature</source>
                    <volume>362</volume>
                    <fpage>59</fpage>
                    <lpage>62</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Cleveland1">
                <label>2</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Cleveland</surname>
                            <given-names>D. W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rothstein</surname>
                            <given-names>J. D</given-names>
                        </name>
                    </person-group>
                    <year>2001</year>
                    <article-title>From Charcot to Lou Gehrig: deciphering selective motor neuron
                        death in ALS.</article-title>
                    <source>Nat Rev Neurosci</source>
                    <volume>2</volume>
                    <fpage>806</fpage>
                    <lpage>819</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Neumann1">
                <label>3</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Neumann</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sampathu</surname>
                            <given-names>D. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kwong</surname>
                            <given-names>L. K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Truax</surname>
                            <given-names>A. C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Micsenyi</surname>
                            <given-names>M. C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and
                        amyotrophic lateral sclerosis.</article-title>
                    <source>Science</source>
                    <volume>314</volume>
                    <fpage>130</fpage>
                    <lpage>133</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kwong1">
                <label>4</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kwong</surname>
                            <given-names>L. K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Neumann</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sampathu</surname>
                            <given-names>D. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>V. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Trojanowski</surname>
                            <given-names>J. Q</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>TDP-43 proteinopathy: the neuropathology underlying major forms
                        of sporadic and familial frontotemporal lobar degeneration and motor neuron
                        disease.</article-title>
                    <source>Acta Neuropathol</source>
                    <volume>114</volume>
                    <fpage>63</fpage>
                    <lpage>70</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-ChenPlotkin1">
                <label>5</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Chen-Plotkin</surname>
                            <given-names>A. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>V. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Trojanowski</surname>
                            <given-names>J. Q</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>TAR DNA-binding protein 43 in neurodegenerative
                        disease.</article-title>
                    <source>Nat Rev Neurol</source>
                    <volume>6</volume>
                    <fpage>211</fpage>
                    <lpage>220</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Pesiridis1">
                <label>6</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Pesiridis</surname>
                            <given-names>G. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>V. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Trojanowski</surname>
                            <given-names>J. Q</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Mutations in TDP-43 link glycine-rich domain functions to
                        amyotrophic lateral sclerosis.</article-title>
                    <source>Hum Mol Genet</source>
                    <volume>18</volume>
                    <fpage>R156</fpage>
                    <lpage>R162</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Gitcho1">
                <label>7</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gitcho</surname>
                            <given-names>M. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baloh</surname>
                            <given-names>R. H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chakraverty</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mayo</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Norton</surname>
                            <given-names>J. B</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>TDP-43 A315T mutation in familial motor neuron
                        disease.</article-title>
                    <source>Ann Neurol</source>
                    <volume>63</volume>
                    <fpage>535</fpage>
                    <lpage>538</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kabashi1">
                <label>8</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kabashi</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Valdmanis</surname>
                            <given-names>P. N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dion</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Spiegelman</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McConkey</surname>
                            <given-names>B. J</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>TARDBP mutations in individuals with sporadic and familial
                        amyotrophic lateral sclerosis.</article-title>
                    <source>Nat Genet</source>
                    <volume>40</volume>
                    <fpage>572</fpage>
                    <lpage>574</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Sreedharan1">
                <label>9</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sreedharan</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Blair</surname>
                            <given-names>I. P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tripathi</surname>
                            <given-names>V. B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hu</surname>
                            <given-names>X</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vance</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>TDP-43 mutations in familial and sporadic amyotrophic lateral
                        sclerosis.</article-title>
                    <source>Science</source>
                    <volume>319</volume>
                    <fpage>1668</fpage>
                    <lpage>1672</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-VanDeerlin1">
                <label>10</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Van Deerlin</surname>
                            <given-names>V. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Leverenz</surname>
                            <given-names>J. B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bekris</surname>
                            <given-names>L. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bird</surname>
                            <given-names>T. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yuan</surname>
                            <given-names>W</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>TARDBP mutations in amyotrophic lateral sclerosis with TDP-43
                        neuropathology: a genetic and histopathological analysis.</article-title>
                    <source>Lancet Neurol</source>
                    <volume>7</volume>
                    <fpage>409</fpage>
                    <lpage>416</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Benajiba1">
                <label>11</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Benajiba</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Le Ber</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Camuzat</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lacoste</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Thomas-Anterion</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>TARDBP mutations in motoneuron disease with frontotemporal lobar
                        degeneration.</article-title>
                    <source>Ann Neurol</source>
                    <volume>65</volume>
                    <fpage>470</fpage>
                    <lpage>473</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kovacs1">
                <label>12</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kovacs</surname>
                            <given-names>G. G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Murrell</surname>
                            <given-names>J. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Horvath</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Haraszti</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Majtenyi</surname>
                            <given-names>K</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>TARDBP variation associated with frontotemporal dementia,
                        supranuclear gaze palsy, and chorea.</article-title>
                    <source>Mov Disord</source>
                    <volume>24</volume>
                    <fpage>1843</fpage>
                    <lpage>1847</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Gitler1">
                <label>13</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gitler</surname>
                            <given-names>A. D</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Beer and bread to brains and beyond: can yeast cells teach us
                        about neurodegenerative disease?</article-title>
                    <source>Neurosignals</source>
                    <volume>16</volume>
                    <fpage>52</fpage>
                    <lpage>62</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Johnson1">
                <label>14</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Johnson</surname>
                            <given-names>B. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McCaffery</surname>
                            <given-names>J. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lindquist</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gitler</surname>
                            <given-names>A. D</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>A yeast TDP-43 proteinopathy model: exploring the molecular
                        determinants of TDP-43 aggregation and cellular toxicity.</article-title>
                    <source>Proc Natl Acad Sci U S A</source>
                    <volume>105</volume>
                    <fpage>6439</fpage>
                    <lpage>6444</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Johnson2">
                <label>15</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Johnson</surname>
                            <given-names>B. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Snead</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>J. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McCaffery</surname>
                            <given-names>J. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shorter</surname>
                            <given-names>J</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>TDP-43 is intrinsically aggregation-prone, and amyotrophic
                        lateral sclerosis-linked mutations accelerate aggregation and increase
                        toxicity.</article-title>
                    <source>J Biol Chem</source>
                    <volume>284</volume>
                    <fpage>20329</fpage>
                    <lpage>20339</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Elden1">
                <label>16</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Elden</surname>
                            <given-names>A. C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kim</surname>
                            <given-names>H. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hart</surname>
                            <given-names>M. P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chen-Plotkin</surname>
                            <given-names>A. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Johnson</surname>
                            <given-names>B. S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Ataxin-2 intermediate-length polyglutamine expansions are
                        associated with increased risk for ALS.</article-title>
                    <source>Nature</source>
                    <volume>466</volume>
                    <fpage>1069</fpage>
                    <lpage>1075</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kwiatkowski1">
                <label>17</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kwiatkowski</surname>
                            <given-names>T. J</given-names>
                            <suffix>Jr</suffix>
                        </name>
                        <name name-style="western">
                            <surname>Bosco</surname>
                            <given-names>D. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Leclerc</surname>
                            <given-names>A. L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tamrazian</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vanderburg</surname>
                            <given-names>C. R</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Mutations in the FUS/TLS gene on chromosome 16 cause familial
                        amyotrophic lateral sclerosis.</article-title>
                    <source>Science</source>
                    <volume>323</volume>
                    <fpage>1205</fpage>
                    <lpage>1208</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Vance1">
                <label>18</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Vance</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rogelj</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hortobagyi</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>De Vos</surname>
                            <given-names>K. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nishimura</surname>
                            <given-names>A. L</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Mutations in FUS, an RNA processing protein, cause familial
                        amyotrophic lateral sclerosis type 6.</article-title>
                    <source>Science</source>
                    <volume>323</volume>
                    <fpage>1208</fpage>
                    <lpage>1211</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Broustal1">
                <label>19</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Broustal</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Camuzat</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Guillot-Noel</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Guy</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Millecamps</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>FUS mutations in frontotemporal lobar degeneration with
                        amyotrophic lateral sclerosis.</article-title>
                    <source>J Alzheimers Dis</source>
                    <volume>22</volume>
                    <fpage>765</fpage>
                    <lpage>769</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Mackenzie1">
                <label>20</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Mackenzie</surname>
                            <given-names>IR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rademakers</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Neumann</surname>
                            <given-names>M. </given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>TDP-43 and FUS in amyotrophic lateral sclerosis and
                        frontotemporal dementia.</article-title>
                    <source>Lancet Neurol</source>
                    <volume>9</volume>
                    <fpage>955</fpage>
                    <lpage>1007</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Huang1">
                <label>21</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Huang</surname>
                            <given-names>E. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Geser</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Trojanowski</surname>
                            <given-names>J. Q</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Strober</surname>
                            <given-names>J. B</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Extensive FUS-immunoreactive pathology in juvenile amyotrophic
                        lateral sclerosis with basophilic inclusions.</article-title>
                    <source>Brain Pathol</source>
                    <volume>20</volume>
                    <fpage>1069</fpage>
                    <lpage>1076</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Munoz1">
                <label>22</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Munoz</surname>
                            <given-names>D. G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Neumann</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kusaka</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yokota</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ishihara</surname>
                            <given-names>K</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>FUS pathology in basophilic inclusion body
                        disease.</article-title>
                    <source>Acta Neuropathol</source>
                    <volume>118</volume>
                    <fpage>617</fpage>
                    <lpage>627</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Urwin1">
                <label>23</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Urwin</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Josephs</surname>
                            <given-names>K. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rohrer</surname>
                            <given-names>J. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mackenzie</surname>
                            <given-names>I. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Neumann</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>FUS pathology defines the majority of tau- and TDP-43-negative
                        frontotemporal lobar degeneration.</article-title>
                    <source>Acta Neuropathol</source>
                    <volume>120</volume>
                    <fpage>33</fpage>
                    <lpage>41</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Doi1">
                <label>24</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Doi</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Koyano</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Suzuki</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nukina</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kuroiwa</surname>
                            <given-names>Y</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>The RNA-binding protein FUS/TLS is a common aggregate-interacting
                        protein in polyglutamine diseases.</article-title>
                    <source>Neurosci Res</source>
                    <volume>66</volume>
                    <fpage>131</fpage>
                    <lpage>133</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Woulfe1">
                <label>25</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Woulfe</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gray</surname>
                            <given-names>D. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mackenzie</surname>
                            <given-names>I. R</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>FUS-immunoreactive intranuclear inclusions in neurodegenerative
                        disease.</article-title>
                    <source>Brain Pathol</source>
                    <volume>20</volume>
                    <fpage>589</fpage>
                    <lpage>597</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Crozat1">
                <label>26</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Crozat</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Aman</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mandahl</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ron</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>1993</year>
                    <article-title>Fusion of CHOP to a novel RNA-binding protein in human myxoid
                        liposarcoma.</article-title>
                    <source>Nature</source>
                    <volume>363</volume>
                    <fpage>640</fpage>
                    <lpage>644</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Zinszner1">
                <label>27</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Zinszner</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sok</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Immanuel</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yin</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ron</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>1997</year>
                    <article-title>TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic
                        shuttling.</article-title>
                    <source>J Cell Sci</source>
                    <volume>110</volume>
                    <issue>Pt 15</issue>
                    <fpage>1741</fpage>
                    <lpage>1750</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kasyapa1">
                <label>28</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kasyapa</surname>
                            <given-names>C. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kunapuli</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cowell</surname>
                            <given-names>J. K</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Mass spectroscopy identifies the splicing-associated proteins,
                        PSF, hnRNP H3, hnRNP A2/B1, and TLS/FUS as interacting partners of the
                        ZNF198 protein associated with rearrangement in myeloproliferative
                        disease.</article-title>
                    <source>Exp Cell Res</source>
                    <volume>309</volume>
                    <fpage>78</fpage>
                    <lpage>85</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Bertolotti1">
                <label>29</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bertolotti</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lutz</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Heard</surname>
                            <given-names>D. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chambon</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tora</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>
                    <year>1996</year>
                    <article-title>hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to
                        the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA
                        polymerase II.</article-title>
                    <source>EMBO J</source>
                    <volume>15</volume>
                    <fpage>5022</fpage>
                    <lpage>5031</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Fujii1">
                <label>30</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Fujii</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Okabe</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Urushido</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Inoue</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yoshimura</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>The RNA binding protein TLS is translocated to dendritic spines
                        by mGluR5 activation and regulates spine morphology.</article-title>
                    <source>Curr Biol</source>
                    <volume>15</volume>
                    <fpage>587</fpage>
                    <lpage>593</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Fujii2">
                <label>31</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Fujii</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Grossenbacher-Zinchuk</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jamari</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wang</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zinchuk</surname>
                            <given-names>V</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>TLS-GFP cannot rescue mRNP formation near spines and spine
                        phenotype in TLS-KO.</article-title>
                    <source>Neuroreport</source>
                    <volume>20</volume>
                    <fpage>57</fpage>
                    <lpage>61</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Alberti1">
                <label>32</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Alberti</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Halfmann</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>King</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kapila</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lindquist</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>A systematic survey identifies prions and illuminates sequence
                        features of prionogenic proteins.</article-title>
                    <source>Cell</source>
                    <volume>137</volume>
                    <fpage>146</fpage>
                    <lpage>158</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Cushman1">
                <label>33</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Cushman</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Johnson</surname>
                            <given-names>B. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>King</surname>
                            <given-names>O. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gitler</surname>
                            <given-names>A. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shorter</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Prion-like disorders: blurring the divide between
                        transmissibility and infectivity.</article-title>
                    <source>J Cell Sci</source>
                    <volume>123</volume>
                    <fpage>1191</fpage>
                    <lpage>1201</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Shorter1">
                <label>34</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Shorter</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lindquist</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Prions as adaptive conduits of memory and
                        inheritance.</article-title>
                    <source>Nat Rev Genet</source>
                    <volume>6</volume>
                    <fpage>435</fpage>
                    <lpage>450</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Fuentealba1">
                <label>35</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Fuentealba</surname>
                            <given-names>R. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Udan</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bell</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wegorzewska</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shao</surname>
                            <given-names>J</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Interaction with polyglutamine aggregates reveals a Q/N-rich
                        domain in TDP-43.</article-title>
                    <source>J Biol Chem</source>
                    <volume>285</volume>
                    <fpage>26304</fpage>
                    <lpage>26314</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Udan1">
                <label>36</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Udan</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baloh</surname>
                            <given-names>R. H</given-names>
                        </name>
                    </person-group>
                    <year>2011</year>
                    <article-title>Implications of the prion-related Q/N domains in TDP-43 and
                        FUS.</article-title>
                    <source>Prion</source>
                    <volume>5</volume>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-LagierTourenne1">
                <label>37</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lagier-Tourenne</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Polymenidou</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cleveland</surname>
                            <given-names>D. W</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>TDP-43 and FUS/TLS: emerging roles in RNA processing and
                        neurodegeneration.</article-title>
                    <source>Hum Mol Genet</source>
                    <volume>19</volume>
                    <fpage>R46</fpage>
                    <lpage>R64</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-LagierTourenne2">
                <label>38</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lagier-Tourenne</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cleveland</surname>
                            <given-names>D. W</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Rethinking ALS: the FUS about TDP-43.</article-title>
                    <source>Cell</source>
                    <volume>136</volume>
                    <fpage>1001</fpage>
                    <lpage>1004</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Cooper1">
                <label>39</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Cooper</surname>
                            <given-names>A. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gitler</surname>
                            <given-names>A. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cashikar</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Haynes</surname>
                            <given-names>C. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hill</surname>
                            <given-names>K. J</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron
                        loss in Parkinson's models.</article-title>
                    <source>Science</source>
                    <volume>313</volume>
                    <fpage>324</fpage>
                    <lpage>328</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Gitler2">
                <label>40</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gitler</surname>
                            <given-names>A. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chesi</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Geddie</surname>
                            <given-names>M. L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Strathearn</surname>
                            <given-names>K. E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hamamichi</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Alpha-synuclein is part of a diverse and highly conserved
                        interaction network that includes PARK9 and manganese
                        toxicity.</article-title>
                    <source>Nat Genet</source>
                    <volume>41</volume>
                    <fpage>308</fpage>
                    <lpage>315</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Scherzinger1">
                <label>41</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Scherzinger</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lurz</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Turmaine</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mangiarini</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hollenbach</surname>
                            <given-names>B</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1997</year>
                    <article-title>Huntingtin-encoded polyglutamine expansions form amyloid-like
                        protein aggregates in vitro and in vivo.</article-title>
                    <source>Cell</source>
                    <volume>90</volume>
                    <fpage>549</fpage>
                    <lpage>558</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Lashuel1">
                <label>42</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lashuel</surname>
                            <given-names>H. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hartley</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Petre</surname>
                            <given-names>B. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Walz</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lansbury</surname>
                            <given-names>P. T</given-names>
                            <suffix>Jr</suffix>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>Neurodegenerative disease: amyloid pores from pathogenic
                        mutations.</article-title>
                    <source>Nature</source>
                    <volume>418</volume>
                    <fpage>291</fpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Tam1">
                <label>43</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tam</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Spiess</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Auyeung</surname>
                            <given-names>W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Joachimiak</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chen</surname>
                            <given-names>B</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>The chaperonin TRiC blocks a huntingtin sequence element that
                        promotes the conformational switch to aggregation.</article-title>
                    <source>Nat Struct Mol Biol</source>
                    <volume>16</volume>
                    <fpage>1279</fpage>
                    <lpage>1285</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Giorgini1">
                <label>44</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Giorgini</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Guidetti</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nguyen</surname>
                            <given-names>Q</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bennett</surname>
                            <given-names>S. C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Muchowski</surname>
                            <given-names>P. J</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>A genomic screen in yeast implicates kynurenine 3-monooxygenase
                        as a therapeutic target for Huntington disease.</article-title>
                    <source>Nat Genet</source>
                    <volume>37</volume>
                    <fpage>526</fpage>
                    <lpage>531</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Willingham1">
                <label>45</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Willingham</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Outeiro</surname>
                            <given-names>T. F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>DeVit</surname>
                            <given-names>M. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lindquist</surname>
                            <given-names>S. L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Muchowski</surname>
                            <given-names>P. J</given-names>
                        </name>
                    </person-group>
                    <year>2003</year>
                    <article-title>Yeast genes that enhance the toxicity of a mutant huntingtin
                        fragment or alpha-synuclein.</article-title>
                    <source>Science</source>
                    <volume>302</volume>
                    <fpage>1769</fpage>
                    <lpage>1772</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Powers1">
                <label>46</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Powers</surname>
                            <given-names>E. T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Morimoto</surname>
                            <given-names>R. I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dillin</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kelly</surname>
                            <given-names>J. W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Balch</surname>
                            <given-names>W. E</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Biological and chemical approaches to diseases of proteostasis
                        deficiency.</article-title>
                    <source>Annu Rev Biochem</source>
                    <volume>78</volume>
                    <fpage>959</fpage>
                    <lpage>991</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Gitcho2">
                <label>47</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gitcho</surname>
                            <given-names>M. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bigio</surname>
                            <given-names>E. H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mishra</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Johnson</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Weintraub</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>TARDBP 3′-UTR variant in autopsy-confirmed frontotemporal
                        lobar degeneration with TDP-43 proteinopathy.</article-title>
                    <source>Acta Neuropathol</source>
                    <volume>118</volume>
                    <fpage>633</fpage>
                    <lpage>645</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Singleton1">
                <label>48</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Singleton</surname>
                            <given-names>A. B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Farrer</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Johnson</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Singleton</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hague</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>alpha-Synuclein locus triplication causes Parkinson's
                        disease.</article-title>
                    <source>Science</source>
                    <volume>302</volume>
                    <fpage>841</fpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Cabrejo1">
                <label>49</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Cabrejo</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Guyant-Marechal</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Laquerriere</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vercelletto</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>De la Fourniere</surname>
                            <given-names>F</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Phenotype associated with APP duplication in five
                        families.</article-title>
                    <source>Brain</source>
                    <volume>129</volume>
                    <fpage>2966</fpage>
                    <lpage>2976</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Huang2">
                <label>50</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Huang</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Xia</surname>
                            <given-names>P. Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhou</surname>
                            <given-names>H</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Sustained expression of TDP-43 and FUS in motor neurons in
                        rodent's lifetime.</article-title>
                    <source>Int J Biol Sci</source>
                    <volume>6</volume>
                    <fpage>396</fpage>
                    <lpage>406</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Bosco1">
                <label>51</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bosco</surname>
                            <given-names>D. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lemay</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ko</surname>
                            <given-names>H. K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhou</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Burke</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Mutant FUS proteins that cause amyotrophic lateral sclerosis
                        incorporate into stress granules.</article-title>
                    <source>Hum Mol Genet</source>
                    <volume>19</volume>
                    <fpage>4160</fpage>
                    <lpage>4175</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Dormann1">
                <label>52</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Dormann</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rodde</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Edbauer</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bentmann</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fischer</surname>
                            <given-names>I</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>ALS-associated fused in sarcoma (FUS) mutations disrupt
                        Transportin-mediated nuclear import.</article-title>
                    <source>EMBO J</source>
                    <volume>29</volume>
                    <fpage>2841</fpage>
                    <lpage>2857</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Gal1">
                <label>53</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gal</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kwinter</surname>
                            <given-names>D. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhai</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jia</surname>
                            <given-names>H</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Nuclear localization sequence of FUS and induction of stress
                        granules by ALS mutants.</article-title>
                    <publisher-name>Neurobiol Aging</publisher-name>
                    <comment> E-pub ahead of print.
                        doi:10.1016/j.neurobiolaging.2010.06.010</comment>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kino1">
                <label>54</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kino</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Washizu</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Aquilanti</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Okuno</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kurosawa</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Intracellular localization and splicing regulation of FUS/TLS are
                        variably affected by amyotrophic lateral sclerosis-linked
                        mutations.</article-title>
                    <source>Nucleic Acids Res</source>
                    <comment> E-pub ahead of print. doi: 10.1093/nar/gkq1162</comment>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ito1">
                <label>55</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ito</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Seki</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tsunoda</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Uchiyama</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Suzuki</surname>
                            <given-names>N</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Nuclear transport impairment of amyotrophic lateral
                        sclerosis-linked mutations in FUS/TLS.</article-title>
                    <source>Ann Neurol</source>
                    <volume>69</volume>
                    <fpage>152</fpage>
                    <lpage>162</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ju1">
                <label>56</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ju</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tardiff</surname>
                            <given-names>D. F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Han</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Divya</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhong</surname>
                            <given-names>Q</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2011</year>
                    <article-title>A yeast model of FUS/TLS-dependent cytotoxicity.</article-title>
                    <source>PLoS Biology</source>
                    <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pbio.1001052" xlink:type="simple">10.1371/journal.pbio.1001052</ext-link></comment>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Goldfarb1">
                <label>57</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goldfarb</surname>
                            <given-names>D. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gariepy</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <collab xlink:type="simple">Schoolnik G, Kornberg RD</collab>
                    <year>1986</year>
                    <article-title>Synthetic peptides as nuclear localization
                        signals.</article-title>
                    <source>Nature</source>
                    <volume>322</volume>
                    <fpage>641</fpage>
                    <lpage>644</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Buchan1">
                <label>58</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Buchan</surname>
                            <given-names>J. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Muhlrad</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Parker</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>P bodies promote stress granule assembly in Saccharomyces
                        cerevisiae.</article-title>
                    <source>J Cell Biol</source>
                    <volume>183</volume>
                    <fpage>441</fpage>
                    <lpage>455</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Colombrita1">
                <label>59</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Colombrita</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zennaro</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fallini</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Weber</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sommacal</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>TDP-43 is recruited to stress granules in conditions of oxidative
                        insult.</article-title>
                    <source>J Neurochem</source>
                    <volume>111</volume>
                    <fpage>1051</fpage>
                    <lpage>1061</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Nonhoff1">
                <label>60</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Nonhoff</surname>
                            <given-names>U</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ralser</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Welzel</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Piccini</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Balzereit</surname>
                            <given-names>D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and
                        interferes with P-bodies and stress granules.</article-title>
                    <source>Mol Biol Cell</source>
                    <volume>18</volume>
                    <fpage>1385</fpage>
                    <lpage>1396</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ralser1">
                <label>61</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ralser</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nonhoff</surname>
                            <given-names>U</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Albrecht</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lengauer</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wanker</surname>
                            <given-names>E. E</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>Ataxin-2 and huntingtin interact with endophilin-A complexes to
                        function in plastin-associated pathways.</article-title>
                    <source>Hum Mol Genet</source>
                    <volume>14</volume>
                    <fpage>2893</fpage>
                    <lpage>2909</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Freibaum1">
                <label>62</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Freibaum</surname>
                            <given-names>B. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chitta</surname>
                            <given-names>R. K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>High</surname>
                            <given-names>A. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Taylor</surname>
                            <given-names>J. P</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Global analysis of TDP-43 interacting proteins reveals strong
                        association with RNA splicing and translation machinery.</article-title>
                    <source>J Proteome Res</source>
                    <volume>9</volume>
                    <fpage>1104</fpage>
                    <lpage>1120</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Buchan2">
                <label>63</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Buchan</surname>
                            <given-names>J. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nissan</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Parker</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Analyzing P-bodies and stress granules in Saccharomyces
                        cerevisiae.</article-title>
                    <source>Methods Enzymol</source>
                    <volume>470</volume>
                    <fpage>619</fpage>
                    <lpage>640</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Zhang1">
                <label>64</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>Y. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Xu</surname>
                            <given-names>Y. F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cook</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gendron</surname>
                            <given-names>T. F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Roettges</surname>
                            <given-names>P</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Aberrant cleavage of TDP-43 enhances aggregation and cellular
                        toxicity.</article-title>
                    <source>Proc Natl Acad Sci U S A</source>
                    <volume>106</volume>
                    <fpage>7607</fpage>
                    <lpage>7612</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Igaz1">
                <label>65</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Igaz</surname>
                            <given-names>L. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kwong</surname>
                            <given-names>L. K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chen-Plotkin</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Winton</surname>
                            <given-names>M. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Unger</surname>
                            <given-names>T. L</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Expression of TDP-43 C-terminal fragments in vitro recapitulates
                        pathological features of TDP-43 proteinopathies.</article-title>
                    <source>J Biol Chem</source>
                    <volume>284</volume>
                    <fpage>8516</fpage>
                    <lpage>8524</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ayala1">
                <label>66</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ayala</surname>
                            <given-names>Y. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zago</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>D'Ambrogio</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Xu</surname>
                            <given-names>Y. F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Petrucelli</surname>
                            <given-names>L</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>Structural determinants of the cellular localization and
                        shuttling of TDP-43.</article-title>
                    <source>J Cell Sci</source>
                    <volume>121</volume>
                    <fpage>3778</fpage>
                    <lpage>3785</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-NguyenBa1">
                <label>67</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Nguyen Ba</surname>
                            <given-names>A. N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pogoutse</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Provart</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Moses</surname>
                            <given-names>A. M</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>NLStradamus: a simple Hidden Markov Model for nuclear
                        localization signal prediction.</article-title>
                    <source>BMC Bioinformatics</source>
                    <volume>10</volume>
                    <fpage>202</fpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-DejesusHernandez1">
                <label>68</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Dejesus-Hernandez</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kocerha</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Finch</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Crook</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baker</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>De novo truncating FUS gene mutation as a cause of sporadic
                        amyotrophic lateral sclerosis.</article-title>
                    <source>Hum Mutat</source>
                    <volume>31</volume>
                    <fpage>E1377</fpage>
                    <lpage>E1389</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Buratti1">
                <label>69</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Buratti</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baralle</surname>
                            <given-names>F. E</given-names>
                        </name>
                    </person-group>
                    <year>2001</year>
                    <article-title>Characterization and functional implications of the RNA binding
                        properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon
                        9.</article-title>
                    <source>J Biol Chem</source>
                    <volume>276</volume>
                    <fpage>36337</fpage>
                    <lpage>36343</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kim1">
                <label>70</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kim</surname>
                            <given-names>S. H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shanware</surname>
                            <given-names>N. P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bowler</surname>
                            <given-names>M. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tibbetts</surname>
                            <given-names>R. S</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Amyotrophic lateral sclerosis-associated proteins TDP-43 and
                        FUS/TLS function in a common biochemical complex to co-regulate HDAC6
                        mRNA.</article-title>
                    <source>J Biol Chem</source>
                    <volume>285</volume>
                    <fpage>34097</fpage>
                    <lpage>34105</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Smith1">
                <label>71</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Smith</surname>
                            <given-names>D. B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Johnson</surname>
                            <given-names>K. S</given-names>
                        </name>
                    </person-group>
                    <year>1988</year>
                    <article-title>Single-step purification of polypeptides expressed in Escherichia
                        coli as fusions with glutathione S-transferase.</article-title>
                    <source>Gene</source>
                    <volume>67</volume>
                    <fpage>31</fpage>
                    <lpage>40</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Forman1">
                <label>72</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Forman</surname>
                            <given-names>M. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Trojanowski</surname>
                            <given-names>J. Q</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>V. M</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>TDP-43: a novel neurodegenerative proteinopathy.</article-title>
                    <source>Curr Opin Neurobiol</source>
                    <volume>17</volume>
                    <fpage>548</fpage>
                    <lpage>555</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kwong2">
                <label>73</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kwong</surname>
                            <given-names>L. K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Uryu</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Trojanowski</surname>
                            <given-names>J. Q</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>V. M</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>TDP-43 proteinopathies: neurodegenerative protein misfolding
                        diseases without amyloidosis.</article-title>
                    <source>Neurosignals</source>
                    <volume>16</volume>
                    <fpage>41</fpage>
                    <lpage>51</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Frankenfield1">
                <label>74</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Frankenfield</surname>
                            <given-names>K. N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Powers</surname>
                            <given-names>E. T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kelly</surname>
                            <given-names>J. W</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Influence of the N-terminal domain on the aggregation properties
                        of the prion protein.</article-title>
                    <source>Protein Sci</source>
                    <volume>14</volume>
                    <fpage>2154</fpage>
                    <lpage>2166</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Hurshman1">
                <label>75</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Hurshman</surname>
                            <given-names>A. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>White</surname>
                            <given-names>J. T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Powers</surname>
                            <given-names>E. T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kelly</surname>
                            <given-names>J. W</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Transthyretin aggregation under partially denaturing conditions
                        is a downhill polymerization.</article-title>
                    <source>Biochemistry</source>
                    <volume>43</volume>
                    <fpage>7365</fpage>
                    <lpage>7381</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Andreu1">
                <label>76</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Andreu</surname>
                            <given-names>J. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Timasheff</surname>
                            <given-names>S. N</given-names>
                        </name>
                    </person-group>
                    <year>1986</year>
                    <article-title>The measurement of cooperative protein self-assembly by turbidity
                        and other techniques.</article-title>
                    <source>Methods Enzymol</source>
                    <volume>130</volume>
                    <fpage>47</fpage>
                    <lpage>59</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Baumer1">
                <label>77</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Baumer</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hilton</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Paine</surname>
                            <given-names>S. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Turner</surname>
                            <given-names>M. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lowe</surname>
                            <given-names>J</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Juvenile ALS with basophilic inclusions is a FUS proteinopathy
                        with FUS mutations.</article-title>
                    <source>Neurology</source>
                    <volume>75</volume>
                    <fpage>611</fpage>
                    <lpage>618</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ritson1">
                <label>78</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ritson</surname>
                            <given-names>G. P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Custer</surname>
                            <given-names>S. K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Freibaum</surname>
                            <given-names>B. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Guinto</surname>
                            <given-names>J. B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Geffel</surname>
                            <given-names>D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>TDP-43 mediates degeneration in a novel Drosophila model of
                        disease caused by mutations in VCP/p97.</article-title>
                    <source>J Neurosci</source>
                    <volume>30</volume>
                    <fpage>7729</fpage>
                    <lpage>7739</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Kabashi2">
                <label>79</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kabashi</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tradewell</surname>
                            <given-names>M. L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dion</surname>
                            <given-names>P. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bercier</surname>
                            <given-names>V</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Gain and loss of function of ALS-related mutations of TARDBP
                        (TDP-43) cause motor deficits in vivo.</article-title>
                    <source>Hum Mol Genet</source>
                    <volume>19</volume>
                    <fpage>671</fpage>
                    <lpage>683</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Barmada1">
                <label>80</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Barmada</surname>
                            <given-names>S. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Skibinski</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Korb</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rao</surname>
                            <given-names>E. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wu</surname>
                            <given-names>J. Y</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Cytoplasmic mislocalization of TDP-43 is toxic to neurons and
                        enhanced by a mutation associated with familial amyotrophic lateral
                        sclerosis.</article-title>
                    <source>J Neurosci</source>
                    <volume>30</volume>
                    <fpage>639</fpage>
                    <lpage>649</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-YegerLotem1">
                <label>81</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Yeger-Lotem</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Riva</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Su</surname>
                            <given-names>L. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gitler</surname>
                            <given-names>A. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cashikar</surname>
                            <given-names>A. G</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Bridging high-throughput genetic and transcriptional data reveals
                        cellular responses to alpha-synuclein toxicity.</article-title>
                    <source>Nat Genet</source>
                    <volume>41</volume>
                    <fpage>316</fpage>
                    <lpage>323</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Hu1">
                <label>82</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Hu</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rolfs</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bhullar</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Murthy</surname>
                            <given-names>T. V</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhu</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Approaching a complete repository of sequence-verified
                        protein-encoding clones for Saccharomyces cerevisiae.</article-title>
                    <source>Genome Res</source>
                    <volume>17</volume>
                    <fpage>536</fpage>
                    <lpage>543</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Buchan3">
                <label>83</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Buchan</surname>
                            <given-names>J. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Parker</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Eukaryotic stress granules: the ins and outs of
                        translation.</article-title>
                    <source>Mol Cell</source>
                    <volume>36</volume>
                    <fpage>932</fpage>
                    <lpage>941</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Giaever1">
                <label>84</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Giaever</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chu</surname>
                            <given-names>A. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ni</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Connelly</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Riles</surname>
                            <given-names>L</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2002</year>
                    <article-title>Functional profiling of the Saccharomyces cerevisiae
                        genome.</article-title>
                    <source>Nature</source>
                    <volume>418</volume>
                    <fpage>387</fpage>
                    <lpage>391</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Goffeau1">
                <label>85</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goffeau</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Barrell</surname>
                            <given-names>B. G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bussey</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Davis</surname>
                            <given-names>R. W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dujon</surname>
                            <given-names>B</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1996</year>
                    <article-title>Life with 6000 genes.</article-title>
                    <source>Science</source>
                    <volume>274</volume>
                    <fpage>546, 563</fpage>
                    <lpage>547</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Tong1">
                <label>86</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tong</surname>
                            <given-names>A. H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lesage</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bader</surname>
                            <given-names>G. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ding</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Xu</surname>
                            <given-names>H</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2004</year>
                    <article-title>Global mapping of the yeast genetic interaction
                        network.</article-title>
                    <source>Science</source>
                    <volume>303</volume>
                    <fpage>808</fpage>
                    <lpage>813</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Tong2">
                <label>87</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tong</surname>
                            <given-names>A. H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Evangelista</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Parsons</surname>
                            <given-names>A. B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Xu</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bader</surname>
                            <given-names>G. D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2001</year>
                    <article-title>Systematic genetic analysis with ordered arrays of yeast deletion
                        mutants.</article-title>
                    <source>Science</source>
                    <volume>294</volume>
                    <fpage>2364</fpage>
                    <lpage>2368</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Sadlish1">
                <label>88</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sadlish</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rampelt</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shorter</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wegrzyn</surname>
                            <given-names>R. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Andreasson</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>Hsp110 chaperones regulate prion formation and propagation in S.
                        cerevisiae by two discrete activities.</article-title>
                    <source>PLoS One</source>
                    <volume>3</volume>
                    <fpage>e1763</fpage>
                    <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0001763" xlink:type="simple">10.1371/journal.pone.0001763</ext-link></comment>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Gilks1">
                <label>89</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gilks</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kedersha</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ayodele</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shen</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Stoecklin</surname>
                            <given-names>G</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2004</year>
                    <article-title>Stress granule assembly is mediated by prion-like aggregation of
                        TIA-1.</article-title>
                    <source>Mol Biol Cell</source>
                    <volume>15</volume>
                    <fpage>5383</fpage>
                    <lpage>5398</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Furukawa1">
                <label>90</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Furukawa</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kaneko</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Matsumoto</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kurosawa</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nukina</surname>
                            <given-names>N</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Cross-seeding fibrillation of Q/N-rich proteins offers new
                        pathomechanism of polyglutamine diseases.</article-title>
                    <source>J Neurosci</source>
                    <volume>29</volume>
                    <fpage>5153</fpage>
                    <lpage>5162</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Doi2">
                <label>91</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Doi</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Okamura</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bauer</surname>
                            <given-names>P. O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Furukawa</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shimizu</surname>
                            <given-names>H</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>RNA-binding protein TLS is a major nuclear aggregate-interacting
                        protein in huntingtin exon 1 with expanded polyglutamine-expressing
                        cells.</article-title>
                    <source>J Biol Chem</source>
                    <volume>283</volume>
                    <fpage>6489</fpage>
                    <lpage>6500</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Deng1">
                <label>92</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Deng</surname>
                            <given-names>H. X</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhai</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bigio</surname>
                            <given-names>E. H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yan</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fecto</surname>
                            <given-names>F</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>FUS-immunoreactive inclusions are a common feature in sporadic
                        and non-SOD1 familial amyotrophic lateral sclerosis.</article-title>
                    <source>Ann Neurol</source>
                    <volume>67</volume>
                    <fpage>739</fpage>
                    <lpage>748</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ash1">
                <label>93</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ash</surname>
                            <given-names>P. E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>Y. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Roberts</surname>
                            <given-names>C. M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Saldi</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hutter</surname>
                            <given-names>H</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Neurotoxic effects of TDP-43 overexpression in C.
                        elegans.</article-title>
                    <source>Hum Mol Genet</source>
                    <volume>19</volume>
                    <fpage>3206</fpage>
                    <lpage>3218</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Liu1">
                <label>94</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Eisenberg</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>3D domain swapping: as domains continue to swap.</article-title>
                    <source>Protein Sci</source>
                    <volume>11</volume>
                    <fpage>1285</fpage>
                    <lpage>1299</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Guo1">
                <label>95</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Guo</surname>
                            <given-names>Z</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Eisenberg</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>Runaway domain swapping in amyloid-like fibrils of T7
                        endonuclease I.</article-title>
                    <source>Proc Natl Acad Sci U S A</source>
                    <volume>103</volume>
                    <fpage>8042</fpage>
                    <lpage>8047</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ogihara1">
                <label>96</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ogihara</surname>
                            <given-names>N. L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ghirlanda</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bryson</surname>
                            <given-names>J. W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gingery</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>DeGrado</surname>
                            <given-names>W. F</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2001</year>
                    <article-title>Design of three-dimensional domain-swapped dimers and fibrous
                        oligomers.</article-title>
                    <source>Proc Natl Acad Sci U S A</source>
                    <volume>98</volume>
                    <fpage>1404</fpage>
                    <lpage>1409</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ling1">
                <label>97</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ling</surname>
                            <given-names>S. C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Albuquerque</surname>
                            <given-names>C. P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Han</surname>
                            <given-names>J. S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lagier-Tourenne</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tokunaga</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>ALS-associated mutations in TDP-43 increase its stability and
                        promote TDP-43 complexes with FUS/TLS.</article-title>
                    <source>Proc Natl Acad Sci U S A</source>
                    <volume>107</volume>
                    <fpage>13318</fpage>
                    <lpage>13323</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Balagopal1">
                <label>98</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Balagopal</surname>
                            <given-names>V</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Parker</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Polysomes, P bodies and stress granules: states and fates of
                        eukaryotic mRNAs.</article-title>
                    <source>Curr Opin Cell Biol</source>
                    <volume>21</volume>
                    <fpage>403</fpage>
                    <lpage>408</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Lin1">
                <label>99</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>C. L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bristol</surname>
                            <given-names>L. A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jin</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dykes-Hoberg</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Crawford</surname>
                            <given-names>T</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1998</year>
                    <article-title>Aberrant RNA processing in a neurodegenerative disease: the cause
                        for absent EAAT2, a glutamate transporter, in amyotrophic lateral
                        sclerosis.</article-title>
                    <source>Neuron</source>
                    <volume>20</volume>
                    <fpage>589</fpage>
                    <lpage>602</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Alberti2">
                <label>100</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Alberti</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gitler</surname>
                            <given-names>A. D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lindquist</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>A suite of Gateway((R)) cloning vectors for high-throughput
                        genetic analysis in Saccharomyces cerevisiae.</article-title>
                    <source>Yeast</source>
                    <volume>24</volume>
                    <fpage>913</fpage>
                    <lpage>919</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Guthrie1">
                <label>101</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Guthrie</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fink</surname>
                            <given-names>G. R</given-names>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>Methods in ezymology: guide to yeast genetics and molecular and
                        cell biology.</article-title>
                    <source>Academic Press</source>
                    <volume>169</volume>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Ito2">
                <label>102</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ito</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fukuda</surname>
                            <given-names>Y</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Murata</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kimura</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>
                    <year>1983</year>
                    <article-title>Transformation of intact yeast cells treated with alkali
                        cations.</article-title>
                    <source>J Bacteriol</source>
                    <volume>153</volume>
                    <fpage>163</fpage>
                    <lpage>168</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Tong3">
                <label>103</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tong</surname>
                            <given-names>A. H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Boone</surname>
                            <given-names>C</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>Synthetic genetic array analysis in Saccharomyces
                        cerevisiae.</article-title>
                    <source>Methods Mol Biol</source>
                    <volume>313</volume>
                    <fpage>171</fpage>
                    <lpage>192</lpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Collins1">
                <label>104</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Collins</surname>
                            <given-names>S. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Schuldiner</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Krogan</surname>
                            <given-names>N. J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Weissman</surname>
                            <given-names>J. S</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>A strategy for extracting and analyzing large-scale quantitative
                        epistatic interaction data.</article-title>
                    <source>Genome Biol</source>
                    <volume>7</volume>
                    <fpage>R63</fpage>
                </element-citation>
            </ref>
            <ref id="pbio.1000614-Rothrock1">
                <label>105</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Rothrock</surname>
                            <given-names>C. R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>House</surname>
                            <given-names>A. E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lynch</surname>
                            <given-names>K. W</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>HnRNP L represses exon splicing via a regulated exonic splicing
                        silencer.</article-title>
                    <source>EMBO J</source>
                    <volume>24</volume>
                    <fpage>2792</fpage>
                    <lpage>2802</lpage>
                </element-citation>
            </ref>
        </ref-list>
        <glossary>
            <title>Abbreviations</title>
            <def-list>
                <def-item>
                    <term>ALS</term>
                    <def>
                        <p>amyotrophic lateral sclerosis</p>
                    </def>
                </def-item>
                <def-item>
                    <term>EM</term>
                    <def>
                        <p>electron microscopy</p>
                    </def>
                </def-item>
                <def-item>
                    <term>FTLD</term>
                    <def>
                        <p>frontotemporal lobar degeneration</p>
                    </def>
                </def-item>
                <def-item>
                    <term>FUS</term>
                    <def>
                        <p>fused in sarcoma</p>
                    </def>
                </def-item>
                <def-item>
                    <term>GPD</term>
                    <def>
                        <p>glyceraldehyde-3-phosphate dehydrogenase</p>
                    </def>
                </def-item>
                <def-item>
                    <term>GST</term>
                    <def>
                        <p>glutathione-S-transferase</p>
                    </def>
                </def-item>
                <def-item>
                    <term>NLS</term>
                    <def>
                        <p>nuclear localization signal</p>
                    </def>
                </def-item>
                <def-item>
                    <term>PABP</term>
                    <def>
                        <p>polyA-binding protein</p>
                    </def>
                </def-item>
                <def-item>
                    <term>P-bodies</term>
                    <def>
                        <p>processing bodies</p>
                    </def>
                </def-item>
                <def-item>
                    <term>PrD</term>
                    <def>
                        <p>prion-like domain</p>
                    </def>
                </def-item>
                <def-item>
                    <term>PrP</term>
                    <def>
                        <p>prion protein</p>
                    </def>
                </def-item>
                <def-item>
                    <term>RRM</term>
                    <def>
                        <p>RNA recognition motif</p>
                    </def>
                </def-item>
                <def-item>
                    <term>SCA</term>
                    <def>
                        <p>spinocerebellar ataxia</p>
                    </def>
                </def-item>
                <def-item>
                    <term>SGA</term>
                    <def>
                        <p>synthetic genetic array</p>
                    </def>
                </def-item>
                <def-item>
                    <term>TDP</term>
                    <def>
                        <p>TAR-DNA-binding protein</p>
                    </def>
                </def-item>
                <def-item>
                    <term>TEV</term>
                    <def>
                        <p>tobacco etch virus</p>
                    </def>
                </def-item>
                <def-item>
                    <term>Tif</term>
                    <def>
                        <p>translation initiation factor</p>
                    </def>
                </def-item>
                <def-item>
                    <term>TLS</term>
                    <def>
                        <p>translocated in liposarcoma</p>
                    </def>
                </def-item>
                <def-item>
                    <term>WT</term>
                    <def>
                        <p>wild-type</p>
                    </def>
                </def-item>
                <def-item>
                    <term>YFP</term>
                    <def>
                        <p>yellow fluorescent protein</p>
                    </def>
                </def-item>
            </def-list>
        </glossary>
        
    </back>
</article>